

# CITATION REPORT

List of articles citing

**Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases**

**DOI: 10.1056/nejm199004053221401**

**New England Journal of Medicine, 1990, 322, 941-9.**

**Source:** <https://exaly.com/paper-pdf/21873660/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1187	The Use of in vitro T Cell Immune Function to Monitor the Course of HIV Infection. <b>1992</b> , 64-75		
1186	Zidovudine update: 1990. <b>1990</b> , 24, 754-60		7
1185	HIV infection in women. <b>1990</b> , 301, 1231-2		5
1184	HIV and surgeons. <b>1990</b> , 301, 1003-4		19
1183	Evaluation of a Hospital Admission HIV Antibody Voluntary Screening Program. <b>1990</b> , 11, 628-634		13
1182	Epidemic in the war zone: AIDS and community survival in New York City. <b>1990</b> , 20, 601-15		28
1181	Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. <b>1990</b> , 113, 276-82		201
1180	NIH conference. Antiretroviral therapy in AIDS. <b>1990</b> , 113, 604-18		46
1179	Current status of HIV therapy: I. Antiretroviral agents. <b>1991</b> , 26, 174-9, 183-4, 189 passim		
1178	Antiretroviral therapy and the use of zidovudine for HIV infection. <b>1990</b> , 4, 529-46		1
1177	Immunologic issues in anti-retroviral therapy. <b>1990</b> , 11, 327-33		9
1176	Zidovudine for early human immunodeficiency virus (HIV) infection: who, when, and how?. <b>1990</b> , 112, 721-3		7
1175	Early HIV infection: to treat or not to treat?. <b>1990</b> , 301, 825-6		14
1174	Early HIV infection. <b>1990</b> , 301, 987		
1173	Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. <b>1990</b> , 301, 1183-8		172
1172	Zidovudine in asymptomatic HIV infection. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 754-6	59.2	1
1171	Erythropoietin for zidovudine-induced anemia. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1069-70	59.2	3

1170	A pilot study of low-dose zidovudine in human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1015-21	59.2	184
1169	Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States. The Sentinel Hospital Surveillance Group. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 213-8	59.2	105
1168	Molecular targets for AIDS therapy. <b>1990</b> , 249, 1533-44		692
1167	Human immunodeficiency virus type 1-infected individuals make autoantibodies that bind to CD43 on normal thymic lymphocytes. <b>1990</b> , 172, 1151-8		61
1166	Design considerations for AIDS trials. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1343-8	59.2	122
1165	HIV-1 Infection In The Correctional Setting. <b>1990</b> , 4, 306-318		7
1164	Effect of Daily Zidovudine (AZT) Pulse-Therapy on Replication of Human Immunodeficiency Virus Type 1 and Type 2 in vitro. <b>1990</b> , 1, 293-298		
1163	Clinical and Epidemiologic Research on HIV Infection and AIDS Among Correctional Inmates: Regulations, Ethics, and Procedures. <b>1990</b> , 14, 482-501		10
1162	A controlled study of early neurologic abnormalities in men with asymptomatic human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 864-70	59.2	135
1161	You can teach an old dog new tricks. How AIDS trials are pioneering new strategies. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1341-3	59.2	37
1160	Hospital-Based Routine HIV Testing Programs. <b>1990</b> , 11, 625-627		2
1159	AIDS in the Nineties: from science to policy. Advances in clinical management. <b>1990</b> , 2, 363-6		1
1158	Considerations for the evaluation of antiretroviral agents in infants and children infected with human immunodeficiency virus: a perspective from the National Cancer Institute. <b>1990</b> , 12 Suppl 5, S561-9		4
1157	Early treatment for HIV: the time has come. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1000-2	59.2	47
1156	Zidovudine for symptomless HIV infection. <b>1990</b> , 335, 821-822		12
1155	How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus?. <b>1990</b> , 1, 141-55		8
1154	Urticarial reaction to zidovudine. <b>1990</b> , 336, 384		6
1153	"False-positive" anti-neutrophil cytoplasmic antibodies in HIV infection. <b>1990</b> , 335, 1227-8		39

1152	Zidovudine for HIV infection without symptoms. <b>1990</b> , 335, 1228		
1151	Uncertainty in estimates of HIV prevalence derived by backcalculation. <b>1990</b> , 1, 105-15		21
1150	Significance of crystal clear urine. <b>1990</b> , 335, 1228		16
1149	Prognostic markers for AIDS. <b>1990</b> , 1, 129-39		3
1148	Lack of cough reflex in aspiration pneumonia. <b>1990</b> , 335, 1228-9		163
1147	New developments in combination chemotherapy of anti-human immunodeficiency virus drugs. <b>1990</b> , 616, 318-27		4
1146	A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1009-14	59.2	282
1145	Response to commentary by N. Fost on Ethical considerations in testing victims of sexual abuse for HIV infection. <b>1990</b> , 14, 604-5		
1144	Predicting the progression to AIDS. <b>1990</b> , 89, 701-5		31
1143	Hierarchical pattern of mucosal candida infections in HIV-seropositive women. <b>1990</b> , 89, 142-6		190
1142	State-of-the-art conference on azidothymidine therapy for early HIV infection. <b>1990</b> , 89, 335-44		55
1141	Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine. <b>1990</b> , 88, 245-265		21
1140	AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. <b>1990</b> , 88, 275-305		19
1139	Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. <b>1990</b> , 117, 799-808		81
1138	A national survey on the care of infants and children with human immunodeficiency virus infection. <b>1991</b> , 118, 817-21		7
1137	Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents. <b>1991</b> , 15, 267-86		57
1136	Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients. <b>1991</b> , 16, 205-12		23
1135	Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. <b>1991</b> , 16, 53-64		33

1134	Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. <b>1991</b> , 338, 265-9	145
1133	Cellular immunology of HIV infection. <b>1991</b> , 11, 65	
1132	Evaluation of two rapid screening assays for the detection of human immunodeficiency virus-1 infection in emergency department patients. <b>1991</b> , 9, 416-20	24
1131	HIV counselling in the 1990s. <b>1991</b> , 337, 950	3
1130	Management of AIDS and its neoplastic complications. <b>1991</b> , 27, 380-9	8
1129	Incidence and prevalence of human immunodeficiency virus infection in a prenatal population undergoing routine voluntary human immunodeficiency virus screening, July 1987 to June 1990. <b>1991</b> , 165, 961-4	13
1128	Serologic and immunologic markers in the course of HIV-1 infection. <b>1991</b> , 9, 1-11	6
1127	Antiretroviral therapy. <b>1991</b> , 9, 13-29	1
1126	Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. <b>1991</b> , 338, 6-9	20
1125	Partner notification for preventing HIV infection. <b>1991</b> , 338, 1112-1113	3
1124	1993 and all that. <b>1991</b> , 338, 1113-1114	2
1123	Infectious diseases and drug abuse. Prevention and treatment in the drug abuse treatment system. <b>1991</b> , 8, 269-75	35
1122	Current surgical controversies over HIV infection. <b>1991</b> , 17, 77-81	2
1121	Zidovudine. <b>1991</b> , 729-765	2
1120	Benefits and costs of HIV testing. <b>1991</b> , 252, 1798-804	30
1119	Is it time for a comprehensive AIDS medical center?. <b>1991</b> , 91, 74-9	7
1118	Poor tolerance of zidovudine in an HIV-asymptomatic patient with alpha-thalassemia. <b>1991</b> , 91, 100-2	2
1117	Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. <b>1991</b> , 91, 471-8	64

1116 Reply. **1991**, 91, 560-561

1115 Prognostic markers for HIV disease progression. **1991**, 91, 561

1114 The reply. **1991**, 91, 561

1113 Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma. **1991**, 90, 2S-7S 23

1112 HIV-1: the infective process in vivo. **1991**, 64, 351-63 109

1111 Immunotherapy of human immunodeficiency virus infection. **1991**, 12, 107-11 28

1110 Drugs, sex and HIV: a mathematical model for New York City. **1991**, 331, 171-87 85

1109 The molecular biology of human immunodeficiency virus type 1 infection. *New England Journal of Medicine*, **1991**, 324, 308-17 59.2 198

1108 Concorde still aloft. **1991**, 338, 1007 1

1107 Clinical significance and characterization of AZT-resistant strains of HIV-1. **1991**, 2, 5-11 2

1106 Preventing the spread of HIV infection. **1991**, 302, 1399-400

1105 Zidovudine-induced macular edema. **1991**, 114, 297-8 17

1104 Zidovudine in asymptomatic HIV infection: knowledge and uncertainty. **1991**, 2, 157-61 3

1103 Testing for HIV antibodies. **1991**, 302, 660-1 4

1102 Hematologic Effects of AIDS Therapies. **1991**, 5, 229-248 15

1101 AIDS and hemophilia. **1991**, 43, 156-72 0

1100 Development of Opportunistic Non-Hodgkin's Lymphomas in Severely Immunosuppressed HIV-Infected Patients Receiving Long-Term Antiretroviral Therapy. **1992**, 196-206

1099 Noninfectious Inflammatory Skin Diseases in HIV-Infected Individuals. **1991**, 9, 531-541 28

1098 HIV-Specific Treatment. **1991**, 9, 585-596

1097 Hematologic Abnormalities in AIDS. **1991**, 5, 195-214

61

1096 Cuba's response to the HIV epidemic. **1991**, 81, 563-7

26

1095 Anorectal Surgery in HIV-seropositive Patients. **1991**, 84, 191-192

3

1094 Facts about AIDS for the Dental Team, Third Edition. **1991**, 122, i-iii

1093 Miscellaneous antibacterial and antiviral drugs. **1991**, 15, 308-326

1092 Chapter 14. Antiviral Agents. **1991**, 26, 133-140

9

1091 Effectiveness of psychoeducational interventions in reducing emotional distress after human immunodeficiency virus antibody testing. **1991**, 48, 143-7

64

1090 Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected patients. **1991**, 35, 1705-9

34

1089 Failure of Prophylactic Zidovudine after Suicidal Self-Inoculation of HIV-Infected Blood. *New England Journal of Medicine*, **1991**, 324, 1062-1062

59.2 30

1088 Zidovudine: counseling strategies and compliance. **1991**, NS31, 38-43

2

1087 Zidovudine overdose. **1991**, 2, 56-7

2

1086 HIV infection in children. **1991**, 302, 921-2

5

1085 Open access clinic providing HIV-I antibody results on day of testing: the first twelve months. **1991**, 302, 1383-6

32

1084 Surrogate end points in clinical trials. **1991**, 302, 63-4

18

1083 Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. **1991**, 81, 1285-90

94

1082 What to do when results of a western blot test are indeterminate. **1991**, 89, 39-40, 45-7

3

1081 Capacity of US labs to provide TLI in support of early HIV-1 intervention. **1991**, 81, 491-4

1

1080	Admission for HIV-1 related disease in a Dublin hospital 1987-1990. <b>1991</b> , 2, 436-9	4
1079	Acetaminophen does not impair clearance of zidovudine. <b>1991</b> , 114, 937-40	16
1078	Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. <b>1991</b> , 114, 798-802	104
1077	The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies. <b>1991</b> , 9, 229-38	19
1076	Human immunodeficiency virus-1 infection in an infertile population. <b>1991</b> , 56, 16-9	1
1075	Antiviral therapy for human immunodeficiency virus infection in children. <b>1991</b> , 38, 133-51	3
1074	Pediatric HIV disease. The newest chronic illness of childhood. <b>1991</b> , 38, 169-94	21
1073	AIDS in Edinburgh drug users: observations on the epidemic and implications for its future management. <b>1991</b> , 22, 113-8	5
1072	HIV/AIDS pathogenesis and treatment: new twists and turns. <b>1991</b> , 3, 537-42	8
1071	High-performance liquid chromatographic analysis of 3'-azido-3'-deoxythymidine monophosphate diglyceride, an anti-HIV glycerophospholipid. <b>1991</b> , 9, 871-5	
1070	Clinical benefits and recovery of delayed-type hypersensitivity in patients with AIDS-related complex treated with IMREG-1 or placebo. <b>1991</b> , 13, 999-1004	4
1069	Inosine pranobex in the treatment of HIV infection: a review. <b>1991</b> , 13 Suppl 1, 19-27	13
1068	HIV-positive women: reasons they are tested for HIV and their clinical characteristics on entry into the health care system. <b>1991</b> , 6, 286-9	22
1067	HIV infection in women: diverse approaches to a growing problem. <b>1991</b> , 6, 380-1	2
1066	Assessing HIV infection in primary care practice. <b>1991</b> , 6, S2-7	7
1065	Recent advances in the medical management of early HIV disease. <b>1991</b> , 6, S7-12	5
1064	Neurologic and psychiatric manifestations of HIV disease. <b>1991</b> , 6, S24-31	7
1063	Caring for women at risk of HIV infection. <b>1991</b> , 6, S40-6	7



1062	Primary care and HIV disease. <b>1991</b> , 6, S56-62	12
1061	Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. <b>1991</b> , 6, 35-40	136
1060	Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. <b>1991</b> , 350, 356-9	95
1059	Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse. <b>1991</b> , 124, 45-62	29
1058	Paediatric HIV infection. <b>1991</b> , 4, 333-59	6
1057	State-of-the-art of zidovudine monitoring. <b>1991</b> , 5, 60-8	15
1056	Fatal disseminated hemorrhagic toxoplasmic encephalitis as the initial manifestation of AIDS. <b>1991</b> , 29, 683-6	17
1055	Plasma adenosine deaminase2 is a marker for human immunodeficiency virus-1 seroconversion. <b>1991</b> , 37, 152-5	14
1054	Stress influences CD4+ lymphocyte counts. <b>1991</b> , 30, 141-2	6
1053	HIV-1: seven facets of functional molecular mimicry. <b>1991</b> , 28, 91-6; discussion 97-9	24
1052	In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir. <b>1991</b> , 65, 283-91	24
1051	Tumor necrosis factor and interferon as prognostic markers in human immunodeficiency virus (HIV) infection. <b>1991</b> , 19 Suppl 2, S93-7	11
1050	Lymphocyte subsets as surrogate markers in antiretroviral therapy. <b>1991</b> , 19 Suppl 2, S103-8	7
1049	Remarkable improvement of neuropsychiatric symptoms in HIV-infected patients after AZT therapy. <b>1991</b> , 69, 409-12	10
1048	Hemophilia treatment in historical perspective: a review of medical and social developments. <b>1991</b> , 62, 5-15	61
1047	Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study. <b>1991</b> , 19, 395-400	6
1046	Testing patients for HIV antibodies is useful for infection control purposes. For the proposition. <b>1991</b> , 1, 5-7	3
1045	A University of California State-supported AIDS research award program--a unique state and university partnership in AIDS research. <b>1991</b> , 11, 65-73	1

1044	Prophylaxis with zidovudine (AZT) after exposure to human immunodeficiency virus: a brief discussion of the issues for emergency physicians. <b>1991</b> , 20, 1351-4	4
1043	The management of HIV-related illness in the emergency department. <b>1991</b> , 20, 1355-65	12
1042	The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. <b>1991</b> , 2, 191-200	12
1041	A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. <b>1991</b> , 164, 43-52	52
1040	Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. <b>1991</b> , 163, 869-72	16
1039	Administration of zidovudine for treatment of infection due to human immunodeficiency virus. <b>1991</b> , 13, 186-7	
1038	Clinical management of fungal infection in patients with AIDS. <b>1991</b> , 28 Suppl A, 67-82	7
1037	In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells. <b>1991</b> , 164, 843-51	24
1036	Antigenic diversity thresholds and the development of AIDS. <b>1991</b> , 254, 963-9	451
1035	The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients. <b>1991</b> , 67, 15-7	2
1034	Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. <b>1991</b> , 164, 1075-81	107
1033	Zidovudine (AZT) for Treatment of Patients Infected With Human Immunodeficiency Virus Type 1. <b>1991</b> , 151, 709	4
1032	Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. <b>1991</b> , 35, 2225-31	31
1031	HIV infection and haemophilia. <b>1991</b> , 66, 364-8	4
1030	Prevalence of Antibody to HIV-1 Among Entrants to US Correctional Facilities. <b>1991</b> , 265, 1129	52
1029	Management of AIDS and infectious complications. <b>1991</b> , 3, 17-24	1
1028	Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. <b>1991</b> , 164, 646-55	122
1027	Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. <b>1991</b> , 164, 973-5	18

1026	In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053). <b>1991</b> , 163, 1219-22	42
1025	Zidovudine-associated embryonic toxicity in mice. <b>1991</b> , 163, 1212-8	55
1024	Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. <b>1991</b> , 13, 537-47	113
1023	A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1018-25	59.2 192
1022	HIV infection and intervention: the first decade. <b>1991</b> , 3, 295-302	7
1021	Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019. <b>1991</b> , 35, 1160-4	3
1020	Feedback from the Sixth International AIDS Conference, San Francisco 1990. <b>1991</b> , 67, 162-71	
1019	Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. <b>1991</b> , 67, 188-93	1
1018	Long-term Safety and Efficacy of Zidovudine in Patients With Advanced Human Immunodeficiency Virus Disease. <b>1991</b> , 151, 981	28
1017	Human Immunodeficiency Virus Infection and the Skin. <b>1991</b> , 151, 1295	28
1016	Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. <b>1991</b> , 48, 695-9	27
1015	Clinical immunology. <b>1991</b> , 67, 963-72	
1014	Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. <b>1991</b> , 35, 322-8	76
1013	Effects of Zidovudine Therapy in Minority and Other Subpopulations With Early HIV Infection. <b>1991</b> , 266, 2709	28
1012	The neurological and electroencephalographic changes in AIDS. <b>1991</b> , 22, 65-70	4
1011	Clinical, virological and immunological features of primary HIV-1 infection. <b>1991</b> , 67, 367-73	2
1010	CD4 Lymphocyte Concentrations in Patients With Newly Identified HIV Infection Attending STD Clinics. <b>1991</b> , 266, 253	7
1009	Infectious Diseases. <b>1991</b> , 265, 3130	

1008	Zidovudine Does It Work for Everyone?. <b>1991</b> , 266, 2750		5
1007	BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. <b>1991</b> , 35, 305-8		159
1006	Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. <b>1991</b> , 88, 3092-6		58
1005	Inosine pranobex for preventing AIDS in patients with HIV infection. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 491-2	59.2	1
1004	A reduced dose of zidovudine in patients with AIDS. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 994-6	59.2	1
1003	Reconstruction and future trends of the AIDS epidemic in the United States. <b>1991</b> , 253, 37-42		211
1002	Performance of patients with early HIV-1 infection on the Stroop Task. <b>1992</b> , 14, 857-68		65
1001	Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. <b>1992</b> , 145, 1196-200		158
1000	Spectrum of Disease in Persons With Human Immunodeficiency Virus Infection in the United States. <b>1992</b> , 267, 1798		121
999	Treatment of HIV infection--progress in perspective. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 484-6	59.2	16
998	The effects on survival of early treatment of human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1037-42	59.2	198
997	Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1697-703	59.2	262
996	HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 445-52	59.2	99
995	A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 857-61	59.2	84
994	A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1842-8	59.2	313
993	A phase I study of amplitgen in human immunodeficiency virus-infected subjects. <b>1992</b> , 166, 717-22		17
992	Interferon-gamma treatment for <i>Mycobacterium avium</i> -intracellular complex bacillemia in patients with AIDS. <b>1992</b> , 166, 686-7		47
991	A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 581-7	59.2	309

990	Early versus late treatment with zidovudine. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 359; author reply 359-60	59.2	1
989	Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. <b>1992</b> , 165, 913-6		56
988	Zidovudine pharmacokinetics during pregnancy. <b>1992</b> , 9, 247-9		26
987	Progression and clinical outcome of infection due to human immunodeficiency virus. <b>1992</b> , 14, 966-72		28
986	The Pharmacological Treatment of Human Immunodeficiency Virus Infection. <b>1992</b> , 5, 121-130		
985	Survival for women and men with AIDS. <b>1992</b> , 166, 74-9		107
984	HIV infection in children. <b>1992</b> , 67, 138-41		11
983	Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. <b>1992</b> , 165, 105-10		34 <sup>o</sup>
982	Estimating Compliance to Study Medication from Serum Drug Levels: Application to an AIDS Clinical Trial of Zidovudine. <b>1992</b> , 48, 619		18
981	Infectious diseases and AIDS. <b>1992</b> , 68, 415-33		
980	Clinical trials of antiviral agents. <b>1992</b> , 29, 97-103		6
979	Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. <b>1992</b> , 36, 1559-62		62
978	Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4+ Cell Counts of 0.50-1.09/L or Less. <b>1992</b> , 152, 2286		15
977	Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. <b>1992</b> , 36, 2381-6		87
976	Medical Care Following HIV Testing. <b>1992</b> , 267, 805		1
975	The Challenge of Minority Recruitment in Clinical Trials for AIDS. <b>1992</b> , 267, 954		77
974	CD4 Lymphocyte Count as an Indicator of Delay in Seeking Human Immunodeficiency Virus-Related Treatment. <b>1992</b> , 152, 1501		10
973	CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. <b>1992</b> , 165, 352-63		259

972	Anti-human immunodeficiency virus effects of zidovudine in combination with double-stranded RNA poly I poly C in T cells and monocytes-macrophages. <b>1992</b> , 8, 1215-9	1
971	Acute Syphilitic Meningitis in a Man With Seropositivity for Human Immunodeficiency Virus Infection and Normal Numbers of CD4 T Lymphocytes. <b>1992</b> , 152, 1326	
970	Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. <b>1992</b> , 36, 1280-3	30
969	A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 437-43	59.2 295
968	HIV drug resistance. <b>1992</b> , 8, 1065-71	63
967	The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. <b>1992</b> , 8, 349-56	36
966	Development of antiviral treatment strategies in murine models. <b>1992</b> , 8, 997-1011	10
965	The use of nucleoside analogues in the treatment of HIV-infected children. <b>1992</b> , 8, 1059-64	4
964	CD4 lymphocyte decline and survival in human immunodeficiency virus infection. The Military Medical Consortium for Applied Retroviral Research. <b>1992</b> , 8, 2039-47	8
963	Hematopoietic growth factors as adjuncts to antiretroviral therapy. <b>1992</b> , 8, 1073-80	15
962	Lymphocyte Subsets in Healthy Children During the First 5 Years of Life. <b>1992</b> , 267, 1484	108
961	Antiretroviral therapy: reverse transcriptase inhibition. <b>1992</b> , 36, 245-54	48
960	Care for AIDS patients in developing countries: a review. <b>1992</b> , 4, 89-102	13
959	Statistical Issues Arising in AIDS Clinical Trials. <b>1992</b> , 87, 562-569	28
958	Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection. <b>1992</b> , 6, 1-8	4
957	Didanosine. <b>1992</b> , 26, 660-70	48
956	Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. <b>1992</b> , 51, 668-76	86
955	Effects of zidovudine treatment on the small intestinal mucosa in patients infected with the human immunodeficiency virus. <b>1992</b> , 102, 1483-92	42

954	Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group. <b>1992</b> , 304, 212-6	18
953	Prevalence of HIV among childbearing women and women having termination of pregnancy: multidisciplinary steering group study. <b>1992</b> , 304, 1082-5	36
952	Zidovudine therapy in combination with intravenous immunoglobulin in HIV infected children. <b>1992</b> , 37, 138-41	2
951	Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group. <b>1992</b> , 304, 13-7	47
950	When to stop a clinical trial. <b>1992</b> , 305, 235-40	165
949	The relationship of total lymphocyte count to CD4 lymphocyte counts in patients infected with human immunodeficiency virus. <b>1992</b> , 304, 79-82	19
948	Acquired immunodeficiency syndrome antibody testing and precautions. <b>1992</b> , 147, 713-6	
947	Latent viruses and mutated oncogenes: no evidence for pathogenicity. <b>1992</b> , 43, 135-204	26
946	Human immunodeficiency virus associated anemia. <b>1992</b> , 76, 699-709	20
945	HIV-1 infection. Diagnosis and management. <b>1992</b> , 76, 1-18	6
944	Medical management of AIDS patients. Tuberculosis and nontuberculous mycobacterial disease. <b>1992</b> , 76, 121-71	41
943	The progression of untreated HIV-1 infection prior to AIDS. <b>1992</b> , 82, 1538-41	22
942	Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy. <b>1992</b> , 27 Suppl 2, 14-25	7
941	Knowledge of therapeutics for human immunodeficiency virus infection among intravenous drug users. <b>1992</b> , 166, 685-6	
940	Ethical dilemmas in HIV infection: what have we learned?. <b>1992</b> , 20, 92-103	4
939	Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. <b>1992</b> , 32, 242-7	16
938	Nail pigmentation associated with zidovudine: a review and report of a case. <b>1992</b> , 24, 557-61	26
937	Viruses, chemotherapy and immunity. <b>1992</b> , 105 Suppl, S85-92	3

936	Trend towards decreased survival in patients infected with HIV resistant to zidovudine. <b>1992</b> , 24, 563-5	2
935	Men who have sex with men: continued challenges for preventing HIV infection and AIDS. <b>1992</b> , 82, 166-7	7
934	Essential HIV/AIDS facts. What you need to know in 1992. <b>1992</b> , 91, 84-6, 89-92, 95	
933	Current status of HIV therapy: I. Antiretroviral agents. <b>1992</b> , 27, 145-56	2
932	Early signs of cognitive deficits among human immunodeficiency virus-positive hemophiliacs. <b>1992</b> , 85, 321-6	17
931	Measuring health status and quality of life in HIV and AIDS. <b>1992</b> , 6, 251-264	35
930	Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction. <b>1992</b> , 27 Suppl 2, 3-4	
929	Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy. <b>1992</b> , 27 Suppl 2, 5-13	2
928	Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects. <b>1992</b> , 27 Suppl 2, 26-36	14
927	Antiviral therapy: current concepts and practices. <b>1992</b> , 5, 146-82	62
926	The role of drugs in the origin of AIDS. <b>1992</b> , 46, 3-15	19
925	Zidovudine overdose in an asymptomatic HIV seropositive patient with hemophilia. <b>1992</b> , 33, 454-7	2
924	The management of HIV disease in pregnancy. <b>1992</b> , 6, 101-24	1
923	Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection. <b>1992</b> , 339, 1436-40	82
922	Hierarchical Bayes Models for the Progression of HIV Infection Using Longitudinal CD4 T-Cell Numbers. <b>1992</b> , 87, 615-626	105
921	Inhibitors of HIV-1 protease. <b>1992</b> , 6, 65-98	103
920	Emergence of mutant HIV reverse transcriptase conferring resistance to AZT. <b>1992</b> , 6, 55-64	2
919	The pharmacoconomics of HIV disease. <b>1992</b> , 1, 161-74	4



918	Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics. <b>1992</b> , 2, 107-17	22
917	Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development. <b>1992</b> , 6, 99-111	2
916	Life-threatening <i>Pseudomonas aeruginosa</i> infections in patients with human immunodeficiency virus infection. <b>1992</b> , 14, 403-11	111
915	Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. <b>1992</b> , 64, 63-70	45
914	AIDS acquired by drug consumption and other noncontagious risk factors. <b>1992</b> , 55, 201-77	40
913	Assessing HIV risk in the general hospital psychiatric clinic. <b>1992</b> , 14, 3-6	15
912	Challenges in the clinical development of antiretroviral drugs. <b>1992</b> , 17, 305-10	1
911	The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro. <b>1992</b> , 17, 169-77	22
910	Animal models for anti-AIDS therapy. <b>1992</b> , 19, 81-109	13
909	Antiviral agents. <b>1992</b> , 67, 160-78	41
908	Risk factors for mother-to-child transmission of HIV-1. <b>1992</b> , 339, 1007-12	464
907	Is the worst of the epidemic over? Back calculation of HIV seroprevalence in The Netherlands. <b>1992</b> , 21, 211-21	2
906	Zidovudine. <b>1992</b> , 339, 626; author reply 627	2
905	Chimiothérapie de l'infection par le virus de l'immunodéficience humaine. État actuel et perspectives. <b>1992</b> , 13, 460-464	
904	Treatment of HIV infection in infants and children. <b>1992</b> , 12, 89-96	
903	Energy transformations in the biosynthesis of the immune system: their relevance to the progression and treatment of AIDS. <b>1992</b> , 38, 315-21	6
902	Seroprevalence of human immunodeficiency virus in parturients at Boston City Hospital: implications for public health and obstetric practice. <b>1992</b> , 167, 622-9	18
901	Beliefs and behavioral intentions regarding human immunodeficiency virus testing among New York City runaways. <b>1992</b> , 13, 576-81	10

900	Voluntary testing for human immunodeficiency virus. <b>1992</b> , 38, 327-327	10
899	The effect of the temperature and duration of sample storage on the measurement of lymphocyte subpopulations from HIV-1-positive and control subjects. <b>1992</b> , 151, 217-25	17
898	HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. <b>1992</b> , 37, 177-88	40
897	Human immunodeficiency virus/acquired immunodeficiency syndrome in pregnant women. <b>1992</b> , 2, 773-803	14
896	Systemic antiviral drugs used in ophthalmology. <b>1992</b> , 37, 19-53	31
895	Human immunodeficiency virus infection in intravenous drug users: a model for primary care. <b>1992</b> , 93, 382-6	74
894	Hepatobiliary complications in patients with human immunodeficiency virus infection. <b>1992</b> , 92, 404-11	110
893	Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. <b>1992</b> , 92, 495-502	206
892	Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes. <b>1992</b> , 154, 155-61	23
891	HIV infection and surgeons. <b>1992</b> , 29, 197-280	4
890	AIDS: Part I. <b>1992</b> , 38, 633-90	3
889	AIDS and hemophilia: experience in the La Paz Hemophilia Center. <b>1992</b> , 22, 281-92	
888	Drug Information Analysis Service. <b>1992</b> , 26, 784-788	
887	When should asymptomatic patients with HIV infection be treated with zidovudine?. <b>1992</b> , 304, 456-7	8
886	Title Page / Contents / Foreword / Preface. <b>1992</b> , I-XIV	
885	Normal Control Values for CD4 and CD8 T Lymphocytes and Their Relevance for HIV-1 Infections. <b>1992</b> , 18-31	
884	Clinical Spectrum of Viral Infections in Hemophilic Patients. <b>1992</b> , 6, 1047-1056	4
883	Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. <b>1992</b> , 11, 1633-55	47

882	The epidemic dynamics of HIV-1 in Italy: modelling the interaction between intravenous drug users and heterosexual population. <b>1992</b> , 11, 1657-84	14
881	Isolation of experimental anti-AIDS glycerophospholipids by micro-preparative reversed-phase high-performance liquid chromatography. <b>1992</b> , 590, 153-61	3
880	Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis. <b>1992</b> , 7, 261-72	20
879	Indeterminate HIV-1 western blots: implications and considerations for widespread HIV testing. <b>1992</b> , 7, 640-5	6
878	Studying treatments for AIDS: new challenges for clinical trials--a panel discussion at the 1990 annual meeting of the Society for Clinical Trials. <b>1992</b> , 13, 272-92	5
877	Evaluation of prognosis and survival of the HIV-infected patient. <b>1992</b> , 74, 386-92	11
876	HIV disease: present status and future directions. <b>1992</b> , 73, 236-43	1
875	The HIV wasting syndrome. <b>1992</b> , 15, 856-7	13
874	Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. <b>1992</b> , 40, 176-82	11
873	Changes in the lymphocyte count and lymphocyte subsets after splenectomy in human immunodeficiency virus infection. <b>1992</b> , 41, 144-6	6
872	Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. <b>1993</b> , 33, 343-9	216
871	What's new in treatment?. <b>1993</b> , 8, 168-73; discussion 181-6	
870	Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. <b>1993</b> , 14, 307-17	90
869	Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues. <b>1993</b> , 71, 392-405	12
868	Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. <b>1993</b> , 45, 397-407	38
867	Interim analyses, stopping rules and data monitoring in clinical trials in Europe. <b>1993</b> , 12, 509-20	23
866	Data monitoring committees and capturing relevant information of high quality. <b>1993</b> , 12, 565-70; discussion 571-3	20
865	Statistical and ethical issues in monitoring clinical trials. <b>1993</b> , 12, 1459-69; discussion 1471-5	56

864	Extending public health surveillance of HIV infection: Information from a five cohort workshop. <b>1993</b> , 12, 2065-2085	7
863	Marker paths. <b>1993</b> , 12, 2099-2126	15
862	Progression of an illness: The life course of AIDS. <b>1993</b> , 21, 301-317	2
861	Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. <b>1993</b> , 240, 479-88	28
860	Reduction of 3'-azido-3'-deoxythymidine to 3'-amino-3'-deoxythymidine in human liver microsomes and its relationship to cytochrome P450. <b>1993</b> , 54, 168-76	30
859	Zidovudine response relationships in early human immunodeficiency virus infection. <b>1993</b> , 54, 556-66	26
858	HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. <b>1993</b> , 362, 355-8	1564
857	Perceptions of AZT: Implications for Adherence to Medical Regimens <sup>1</sup> . <b>1993</b> , 1, 39-54	17
856	Asymptomatic women at high risk of vertical HIV-1 transmission to their fetuses. <b>1993</b> , 100, 334-7	14
855	Prevention of HIV infection in women. <b>1993</b> , 22, 128-34	8
854	Advances in pharmacotherapy: treatment of HIV infection. <b>1993</b> , 18, 375-388	
853	Monitoring of clinical trials: issues and recommendations. <b>1993</b> , 14, 183-97	120
852	Performance evaluation in multicenter clinical trials: development of a model by the AIDS Clinical Trials Group. <b>1993</b> , 14, 523-37	9
851	Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. <b>1993</b> , 14, 6-18	8
850	Gastrointestinal symptoms in ambulatory HIV-infected patients. <b>1993</b> , 38, 1388-94	40
849	Proportional hazards (Cox) regression. <b>1993</b> , 8, 702-11	65
848	Rural HIV infection: the window of opportunity for action is still wide open. <b>1993</b> , 8, 210-2	8
847	Perceived needs and unmet needs for formal services among people with HIV disease. <b>1993</b> , 18, 11-23	49

846	Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients. <b>1993</b> , 12, 618-21	2
845	Human genetic therapy. <b>1993</b> , 14, 451-546	6
844	Smoothed nonparametric back-projection of AIDS incidence data with adjustment for therapy. <b>1993</b> , 118, 1-23	11
843	In-vivo effect of interleukin 3 and erythropoietin, either alone or in combination, on the hematopoietic toxicity associated with zidovudine. <b>1993</b> , 5, 62-71	4
842	The immunopathogenesis of human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1993</b> , 328, 327-35	59.2 855
841	Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. <b>1993</b> , 95, 629-35	53
840	In vitro antiviral activity of polyoxomolybdates. Mechanism of inhibitory effect of PM-104 (NH <sub>4</sub> ) <sub>12</sub> H <sub>2</sub> (Eu <sub>4</sub> (MoO <sub>4</sub> )(H <sub>2</sub> O) <sub>16</sub> (Mo <sub>7</sub> O <sub>24</sub> ) <sub>4</sub> ).13H <sub>2</sub> O on human immunodeficiency virus type 1. <b>1993</b> , 20, 317-31	48
839	Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. <b>1993</b> , 123, 1-8	82
838	Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. <b>1993</b> , 122, 137-44	95
837	Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. <b>1993</b> , 122, 966-73	11
836	AIDS-related cholangitis: diagnostic features and course in 15 patients. <b>1993</b> , 17, 34-9	127
835	Manifestations cliniques et biologiques de la primo-infection par le virus de l'immunodficiency humaine : revue de la littfature. <b>1993</b> , 23, 643-652	2
834	Protein Binding of Zidovudine in the Sera of Healthy Controls and Patients Infected with Human Immunodeficiency Virus. <b>1993</b> , 5, 166-172	3
833	Zidovudine toxicity. Clinical features and management. <b>1993</b> , 8, 312-20	34
832	Comparative pharmacokinetics of antiviral nucleoside analogues. <b>1993</b> , 24, 101-23	108
831	Antiviral therapy in human immunodeficiency virus infections. Current status (Part II). <b>1993</b> , 45, 637-53	16
830	Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. <b>1993</b> , 46, 515-578	67
829	Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus. <b>1993</b> , 3, 309-37	6

828	Zidovudine Still First Choice in HIV Treatment but Early Use is Questioned. <b>1993</b> , 2, 4-7	
827	Future Therapies for HIV Disease. <b>1993</b> , 2, 7-8	
826	The AIDS Epidemic: Estimating Survival After AIDS Diagnosis from Surveillance Data. <b>1993</b> , 88, 26	11
825	Size and Power of Two-Sample Tests of Repeated Measures Data. <b>1993</b> , 49, 1022	57
824	The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. <b>1993</b> , 168, 1510-6	141
823	Human immunodeficiency virus infection in pregnancy. <b>1993</b> , 7, 45-74	12
822	Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. <b>1993</b> , 341, 889-90	237
821	Evolution des caractéristiques cliniques et immunologiques au moment du diagnostic de SIDA : résultats de la cohorte Aquitaine, 1985-1991. <b>1993</b> , 23, 902-907	
820	Antiviral therapy of chronic hepatitis B: past, present, and future. <b>1993</b> , 17 Suppl 3, S56-63	21
819	Progress in the understanding of HIV infection: an overview. <b>1993</b> , 29, 1-21	8
818	The Concorde trial. <b>1993</b> , 341, 1276-1277	5
817	Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. <b>1993</b> , 342, 700-3	66
816	Implications for trials in progress of publication of positive results. <b>1993</b> , 342, 653-7	26
815	On stopping a trial before its time. <b>1993</b> , 342, 1311-1312	5
814	Early announcements. <b>1993</b> , 342, 1001-1002	7
813	Human immunodeficiency virus infections. <b>1993</b> , 41, 307-319	
812	Antiviral therapy for HIV infection in infants and children. <b>1993</b> , 693, 166-77	
811	Centers for Disease Control programs in flow cytometric immunophenotyping. <b>1993</b> , 677, 40-2	3

810	Characterization of T lymphocyte subset alterations by flow cytometry in HIV disease. <b>1993</b> , 677, 126-37	25
809	HIV Disease: Current Concepts. <b>1993</b> , 71, 261-274	14
808	A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. <b>1993</b> , 4, 659-80	22
807	Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. <b>1993</b> , 9, 91-8	106
806	Zidovudine in HIV infection. <b>1993</b> , 25, 213-4	
805	Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. <b>1993</b> , 37, 1207-13	211
804	Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. <b>1993</b> , 37, 512-22	13
803	Partner notification for HIV infection in the United Kingdom: a look back on seven years experience in Newcastle upon Tyne. <b>1993</b> , 69, 94-7	5
802	Maternal Transmission of the Human Immunodeficiency Virus: Can It Be Prevented?. <b>1993</b> , 2, 231-242	5
801	Quantitation of unintegrated HIV-1 DNA in asymptomatic patients in the presence or absence of antiretroviral therapy. <b>1993</b> , 9, 183-7	14
800	Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. <b>1993</b> , 37, 2153-8	26
799	A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. <b>1993</b> , 167, 526-32	132
798	Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. <b>1993</b> , 168, 733-6	52
797	Gender differences in reported AIDS-indicative diagnoses. <b>1993</b> , 168, 61-7	49
796	A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. <b>1993</b> , 168, 1374-9	86
795	Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. <b>1993</b> , 168, 825-35	89
794	Intermittent Zidovudine Regimen in Patients with Symptomatic HIV Infection and Previous Haematological Toxicity. <b>1993</b> , 4, 139-143	2
793	Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virus. <b>1993</b> , 16 Suppl 1, S32-9	3

792	Primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia. <i>New England Journal of Medicine</i> , <b>1993</b> , 328, 1499	59.2	
791	Therapy for human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1993</b> , 328, 1686-95	59.2	144
790	Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 297-303	59.2	193
789	Zidovudine now or later?. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 351-2	59.2	16
788	Neonatal HIV seroprevalence studies. A critique of national and international practices. <b>1993</b> , 14, 413-61		2
787	Screening for HIV infection in pregnancy. <b>1993</b> , 5, 135-40		20
786	Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. <b>1993</b> , 16 Suppl 1, S22-5		18
785	Effect of didanosine on human immunodeficiency virus viremia and antigenemia in patients with advanced disease: correlation with clinical response. <b>1993</b> , 167, 30-5		15
784	Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. <b>1993</b> , 16, 816-22; discussion 823-4		4
783	Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. <b>1993</b> , 16 Suppl 1, S46-51		19
782	Early identification of human immunodeficiency virus-infected asymptomatic subjects susceptible to zidovudine by quantitative viral coculture and reverse transcription-linked polymerase chain reaction. <b>1993</b> , 167, 1014-20		15
781	Mathematical Models and the Design of Public Health Policy: Hiv and Antiviral Therapy. <b>1993</b> , 35, 1-16		14
780	Oral Adverse Effects of Medical Management in Patients With HIV Infection. <b>1993</b> , 7, 304-311		2
779	Early Intervention for HIV Infection in a Gynecologic Setting. <b>1993</b> , 2, 343-347		
778	A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 1065-72	59.2	143
777	Practical Use of Hematopoietic Growth Factors in HIV Infection. <b>1993</b> , 2, 119-122		
776	Preventive Health Care for Adults With HIV Infection. <b>1993</b> , 269, 1144		24
775	AIDS: the statistical basis for public health. <b>1993</b> , 2, 75-91		3



774	2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. <b>1993</b> , 167, 21-9	146
773	The AIDS Epidemic: Estimating Survival After AIDS Diagnosis From Surveillance Data. <b>1993</b> , 88, 26-36	22
772	Molecular Targets of Gene Transfer Therapy for HIV Infection. <b>1993</b> , 269, 2880	16
771	Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. <b>1993</b> , 50, 167-71	63
770	Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. <b>1993</b> , 37, 115-9	27
769	Present status and future prospects for HIV therapies. <b>1993</b> , 260, 1286-93	189
768	Impairment of tritan colour vision after initiation of treatment with zidovudine in patients with HIV disease or AIDS. <b>1993</b> , 77, 315-6	11
767	Partner notification for human immunodeficiency virus infection in Colorado: results across index case groups and costs. <b>1993</b> , 4, 26-32	33
766	Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. <b>1993</b> , 118, 681-8	619
765	Development of outcome-based practice guidelines: a method for structuring problems and synthesizing evidence. <b>1993</b> , 19, 248-63	30
764	Abnormalities of Immune Regulation in Human Immunodeficiency Virus Infection. <b>1993</b> , 33, S71-S75	2
763	Case report: increase in CD4 lymphocyte counts after splenectomy in HIV-infected patients. <b>1993</b> , 306, 105-10	10
762	Zidovudine dosage. Nordic Medical Research Councils' HIV Therapy Group. <b>1993</b> , 307, 682-3	3
761	After Concorde. <b>1993</b> , 306, 1016-7	6
760	Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. <b>1993</b> , 307, 20-3	48
759	Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. <b>1993</b> , 307, 1322-5	17
758	A checklist for evaluation of HIV-infected patients. <b>1993</b> , 93, 101-4, 107-8	1
757	Are HIV-infected injection drug users taking HIV tests?. <b>1993</b> , 83, 1414-7	8

756	The underrecognition of HIV infection in women in an inner-city emergency room. <b>1993</b> , 83, 363-8	47
755	pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. <b>1993</b> , 37, 1480-7	47
754	Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. <b>1993</b> , 83, 1385-9	19
753	Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. <b>1993</b> , 90, 25-9	82
752	Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. <b>1993</b> , 90, 6405-9	101
751	Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. <b>1993</b> , 115, 575-82	293
750	Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. <b>1993</b> , 137, 423-38	151
749	Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. <b>1993</b> , 138, 952-64	73
748	Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. <b>1993</b> , 137, 1229-40	45
747	Women and AIDS. <b>1993</b> , 33, 341-50	8
746	Prophylaxis of HIV infection following occupational exposure. <b>1993</b> , 27, 1243-56	3
745	CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. <b>1993</b> , 118, 674-80	127
744	Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. <b>1993</b> , 119, 786-93	91
743	Insight into the infection dynamics of the AIDS epidemic: a birth cohort analysis of New York City AIDS mortality. <b>1993</b> , 138, 1093-104	12
742	Placental transport of Zidovudine in the rhesus monkey. <b>1993</b> , 1, 137-43	
741	Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. <b>1993</b> , 118, 762-9	71
740	Who Should Be Screened for HIV Infection?. <b>1993</b> , 153, 1107	25
739	Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. <b>1993</b> , 118, 321-30	42

738	Outcome of Intensive Care for Patients with AIDS. <b>1993</b> , 9, 107-114	22
737	Pathogenesis, Natural History, and Classification of HIV Infection. <b>1993</b> , 9, 13-29	1
736	Treatment of HIV Infection in Infancy. <b>1994</b> , 21, 163-177	8
735	Appendix: Effect of HIV Treatment on Cognition, Behavior, and Emotion. <b>1994</b> , 17, 227-230	6
734	Human Immunodeficiency Virus (HIV) Infection. <b>1994</b> , 120, 310	13
733	Utilization of AZT administration for the treatment of cancer and AIDS. <b>1994</b> , 3, 379-389	4
732	Use of Preventive Interventions by Persons Infected with Type-1 Human Immunodeficiency Virus (HIV-1). <b>1994</b> , 10, 259-266	9
731	Human immunodeficiency virus infection and pregnancy. <b>1994</b> , 2, 76-82	
730	Antiretroviral therapy in HIV-infected adults. Which regimens are recommended?. <b>1994</b> , 95, 47-50, 53-5	1
729	Use of anonymous newborn serosurveys to evaluate antenatal HIV screening programmes. <b>1994</b> , 1, 176-9	22
728	Improved survival for patients with AIDS-related Kaposi's sarcoma. <b>1994</b> , 12, 1910-6	36
727	Psychological Impact of HIV Disease and Implications for Intervention. <b>1994</b> , 17, 163-182	115
726	Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. <b>1994</b> , 38, 348-52	15
725	Quantitative relationships between zidovudine exposure and efficacy and toxicity. <b>1994</b> , 38, 1726-31	18
724	Zidovudine Improves Psoriasis in Human Immunodeficiency Virus Positive Males. <b>1994</b> , 130, 447	35
723	Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. <b>1994</b> , 51, 943-50	19
722	Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. <b>1994</b> , 169, 713-21	29
721	Implications of Generalists' Slow Adoption of Zidovudine in Clinical Practice. <b>1994</b> , 154, 1497	27

720	Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers. <b>1994</b> , 154, 2745-9	16
719	Comparison of Long-term Prognosis of Patients With AIDS Treated and Not Treated With Zidovudine. <b>1994</b> , 271, 1088	19
718	Changes in AIDS Survival Time in Two San Francisco Cohorts of Homosexual Men, 1983 to 1993. <b>1994</b> , 271, 1083	34
717	Drug Combination of AZT and ddI: Synergism of Action and Prevention of Appearance of AZT-Resistance. <b>1994</b> , 5, 51-55	8
716	Antiretroviral Treatment of Men Infected With Human Immunodeficiency Virus Type 1 Reduces the Incidence of Heterosexual Transmission. <b>1994</b> , 154, 1971	52
715	Markers predicting progression of human immunodeficiency virus-related disease. <b>1994</b> , 7, 14-28	85
714	Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. <b>1994</b> , 10, 395-403	57
713	Evolving understanding of the immunopathogenesis of HIV. <b>1994</b> , 10, 887-92	7
712	Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. <b>1994</b> , 5 Suppl 2, 41-6	17
711	A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. <b>1994</b> , 169, 9-17	81
710	Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. AIDS Clinical Trial Research Group 047. <b>1994</b> , 170, 1165-71	6
709	CD4+ T-Lymphocyte Measures in the Treatment of Individuals Infected With Human Immunodeficiency Virus Type 1. <b>1994</b> , 154, 1561	23
708	Human Immunodeficiency Virus Infection. <b>1994</b> , 18, 963-973	2
707	The CD4 + Lymphocyte and the Evaluation of Antiviral Drug Therapy in HIV Infection. <b>1994</b> , 28, 835-849	1
706	Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay. <b>1994</b> , 38, 2689-94	1
705	The Duration of Zidovudine Benefit in Persons With Asymptomatic HIV Infection. <b>1994</b> , 272, 437	48
704	Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. <b>1994</b> , 38, 1036-40	9
703	Decision Analytic Modeling: Some Uses in the Evaluation of New Pharmaceuticals. <b>1994</b> , 28, 691-707	21

702	Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. <b>1994</b> , 169, 411-5		61
701	What to do when zidovudine fails. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 706-7	59.2	2
700	Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 738-43	59.2	131
699	Racial differences in the use of drug therapy for HIV disease in an urban community. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 763-8	59.2	275
698	Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. <b>1994</b> , 169, 1236-43		93
697	Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. <b>1994</b> , 169, 416-9		29
696	Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. <b>1994</b> , 169, 1351-5		32
695	Spontaneous in vitro anti-human immunodeficiency virus type 1 antibody secretion by peripheral blood mononuclear cells is related to disease progression in zidovudine-treated adults. <b>1994</b> , 170, 1376-83		14
694	Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. <b>1994</b> , 170, 1394-403		67
693	Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy. <b>1994</b> , 170, 202-5		13
692	Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. <b>1994</b> , 169, 739-45		103
691	Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. <b>1994</b> , 169, 28-36		111
690	Management of antiretroviral drug therapy in human immunodeficiency virus infection. <b>1994</b> , 31, 169-96		2
689	Early intervention in HIV infection: where are we?. <b>1994</b> , 10, 893-9		3
688	A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents. <b>1994</b> , 10, 413-20		74
687	Early Intervention in HIV Infection. <b>1994</b> , 8, 310-316		
686	Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. <b>1994</b> , 72, 111-116		2
685	In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. <b>1994</b> , 4, 5-8		1

684	In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. <b>1994</b> , 4, 9-12	1
683	Zidovudine should be given before HIV-positive individuals develop symptoms. <b>1994</b> , 4, 75-80	3
682	Selecting the best dose when a monotonic dose-response relation exists. <b>1994</b> , 13, 87-95	5
681	Estimation of time since infection using longitudinal disease-marker data. <b>1994</b> , 13, 231-44	4
680	The utility of large, simple trials in the evaluation of AIDS treatment strategies. <b>1994</b> , 13, 405-15	7
679	Surrogate markers in AIDS and cancer trials. <b>1994</b> , 13, 1423-35; discussion 1437-40	91
678	Discussion of surrogate markers in aids and cancer trials <b>1994</b> , 13, 1437-1440	9
677	Considerations in choice of a clinical endpoint for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). <b>1994</b> , 13, 2107-25	78
676	The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population. <b>1994</b> , 13, 2127-39	18
675	Assessing drug compliance using longitudinal marker data, with application to AIDS. <b>1994</b> , 13, 2141-53	23
674	Some statistical issues in HIV vaccine trials. <b>1994</b> , 13, 2155-77	18
673	Adverse drug reactions in HIV seropositive patients. <b>1994</b> , 3, 31-40	1
672	Statistical issues in designing clinical trials of aids treatments and vaccines. <b>1994</b> , 42, 123-135	6
671	Quantification of 3'-amino-3'-deoxythymidine, a toxic catabolite of 3'-azido-3'-deoxythymidine (zidovudine) in human plasma by high-performance liquid chromatography using precolumn derivatization with fluoescamine and fluorescence detection. <b>1994</b> , 656, 389-96	16
670	Acquired immunodeficiency syndrome (AIDS) in homosexual men: Psychological distress and psychotherapy. <b>1994</b> , 1, 69-81	6
669	Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. <b>1994</b> , 38, 2792-7	20
668	Proficiency of internal medicine residents in outpatient care of patients with HIV infection. <b>1994</b> , 9, 459-61	2
667	Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. <b>1994</b> , 140, 105-30	159

666	Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. <b>1994</b> , 56, 272-8	79
665	Working towards a European strategy for intervention to reduce vertical transmission of HIV. <b>1994</b> , 101, 192-6	14
664	Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. <b>1994</b> , 86, 174-9	21
663	Epidemiology and clinical manifestations of human immunodeficiency virus infection. <b>1994</b> , 29, 230-41	1
662	The molecular and cellular biology of the human immunodeficiency virus. <b>1994</b> , 4, 184-188	
661	Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. <b>1994</b> , 38, 799-804	44
660	Factors associated with initiation of primary medical care for HIV-infected persons. <b>1994</b> , 97, 347-53	40
659	Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. <b>1994</b> , 47, 1003-12	52
658	A transmission model for HIV with application to the Australian epidemic. <b>1994</b> , 119, 205-24	10
657	Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. <b>1994</b> , 343, 871-881	380
656	Zidovudine for mother, fetus, and child: hope or poison?. <b>1994</b> , 344, 207-9	18
655	Increased hematopoietic toxicity following administration of interferon- $\gamma$ with combination dideoxynucleoside therapy (zidovudine plus DDI) administered in normal mice. <b>1994</b> , 56, PL71-PL81	2
654	Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. <b>1994</b> , 24, 59-67	20
653	New viral markers and their detection methods for clinical studies of human immunodeficiency virus type 1 infection. <b>1994</b> , 14, 95-100	
652	In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS?. <b>1994</b> , 48, 51-3	13
651	Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 1173-80	59.2 3081
650	Are HIV-1 seropositive subjects submitted to one of the innumerable AZT randomized double-blind trials, definitely victims of cross and/or common resistance to all virostatics, even in combinations?. <b>1994</b> , 48, 49-50	
649	Pharmacokinetics of Zidovudine in Children with Symptomatic HIV Infection. <b>1994</b> , 7, 143-147	5

648	The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. <b>1994</b> , 169, 968-74	347
647	5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. <b>1994</b> , 38, 1590-603	56
646	Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. <b>1994</b> , 139, 1077-87	67
645	Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. <b>1994</b> , 34, 782-6	9
644	The Effect of Zidovudine on Erythrocyte Mean Corpuscular Volume in Asymptomatic HIV-Infected Individuals. <b>1994</b> , 11, 141-155	1
643	Treatment of human immunodeficiency virus infection and its associated complications in children. <b>1994</b> , 34, 17-29	4
642	Pharmacologic therapy for human immunodeficiency virus infection: a review. <b>1994</b> , 307, 368-73	10
641	Inhibitors of HIV proteinase. <b>1994</b> , 3, 273-286	29
640	Pneumonia in patients with HIV infection. <b>1994</b> , 78, 1067-79	15
639	Economics and the treatment of AIDS: a preliminary assessment. <b>1994</b> , 26, 1093-1098	2
638	The Use of Backcalculation to Estimate the Prevalence of Severe Immunodeficiency Induced by Human Immunodeficiency Virus in England and Wales. <b>1994</b> , 157, 41	2
637	Using CD4 counts to evaluate the stages and epidemiology of HIV infection in South Carolina public clinic patients. <b>1994</b> , 84, 377-81	4
636	Viral infections of the brain. <b>1995</b> , 5 Suppl 1, S40-4	9
635	Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm <sup>3</sup> . A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. <b>1995</b> , 123, 561-71	27
634	Outcome of intensive care in patients with HIV infection. <b>1995</b> , 107, 506-10	79
633	Prediction of Cost-effectiveness for Human Immunodeficiency Virus (HIV) Screening Program in Japan. <b>1995</b> , 5, 35-41	
632	Molecular pathogenesis of AIDS-related lymphomas. <b>1995</b> , 67, 113-53	53
631	The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. <b>1995</b> , 16, 408-21	55



630	Ethical aspects of assisted reproduction in AIDS patients. <b>1995</b> , 12, 537-42	11
629	Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. <b>1995</b> , 23, 344-8	11
628	Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. <b>1995</b> , 95, 51-70	9
627	AZT toxicity and AIDS prophylaxis: is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter?. <b>1995</b> , 95, 91-101	5
626	The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. <b>1995</b> , 95, 103-9	18
625	Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. <b>1995</b> , 14, 512-9	9
624	Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs. <b>1995</b> , 14, 400-5	1
623	A defective HIV-1 vector for gene transfer to human lymphocytes. <b>1995</b> , 73, 279-88	9
622	Zidovudine and HIV: Mathematical models of within-host population dynamics. <b>1995</b> , 5, 141-147	21
621	Prophylaxis for <i>Pneumocystis carinii</i> pneumonia: its impact on the natural history of HIV infection in men with haemophilia. <b>1995</b> , 1, 37-44	2
620	Didanosine treatment of haemophilic patients infected with HIV. <b>1995</b> , 1, 122-5	1
619	Management of patients with HIV and/or hepatitis. <b>1995</b> , 1 Suppl 1, 26-34	3
618	Three-colour flow cytometric immunophenotyping in HIV-patients; comparison to dual-colour protocols. <b>1995</b> , 41, 114-20	5
617	Community treatment of HIV-1: initial stage and asymptotic dynamics. <b>1995</b> , 35, 75-81	16
616	Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. <b>1995</b> , 41, 303-15	398
615	Antiviral properties of simple difunctionalized enols targeted to the HIV-1 protease. <b>1995</b> , 27, 205-18	2
614	Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. <b>1995</b> , 122, 24-32	84
613	AIDS: Lessons from the Last Decade and Prospects for the Future. <b>1995</b> , 74, 329-336	

612	Recent advances: antiinfectives. <b>1995</b> , 29, 1035-40		3
611	Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. <b>1995</b> , 122, 856-66		48
610	Factors Associated with Initiation of Zidovudine in a Cohort of Injection Drug Users. <b>1995</b> , 25, 225-233		13
609	Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients. <b>1995</b> , 11, 1373-8		22
608	Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1662-9	59.2	470
607	Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. <b>1995</b> , 11, 473-9		23
606	High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. <b>1995</b> , 171, 537-45		274
605	Distribution of CD4+ T Lymphocytes at Diagnosis of Acquired Immunodeficiency Syndrome Defining and Other Human Immunodeficiency Virus Related Illnesses. <b>1995</b> , 155, 1537		57
604	Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. <b>1995</b> , 20, 352-62		17
603	A controlled trial of zidovudine in primary human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 408-13	59.2	274
602	A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 401-7	59.2	112
601	Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. <b>1995</b> , 172, 59-69		23
600	Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. <b>1995</b> , 171, 297-304		13
599	Antiretroviral therapy: reference guide to major clinical trials in patients infected with human immunodeficiency virus. <b>1995</b> , 20, 1145-51		1
598	A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. <b>1995</b> , 172, 1246-52		28
597	Controversies in anti-retroviral therapy of adults. <b>1995</b> , 35, 245-62		4
596	Dose-related activity of stavudine in patients infected with human immunodeficiency virus. <b>1995</b> , 171 Suppl 2, S131-9		49
595	The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. <b>1995</b> , 172, 97-104		13

594	Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine. <b>1995</b> , 155, 961	28
593	Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. <b>1995</b> , 21, 930-7	3
592	Clinical aspects of human immunodeficiency virus disease: clinical rationale for treatment. <b>1995</b> , 171 Suppl 2, S81-7	4
591	Estimation of Individual and Population Noncompliance Using Longitudinal Marker Data, with Application to AIDS. <b>1995</b> , 29, 1601S-1614S	
590	A Health Services Approach for the Evaluation of Innovative Pharmaceutical and Biotechnology Products. <b>1995</b> , 29, 1405-1414	8
589	Strategies for control of zidovudine concentrations in serum. <b>1995</b> , 39, 2792-7	11
588	Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. <b>1995</b> , 172, 1480-5	29
587	Interpretation of Subgroup Analyses in Clinical Trials. <b>1995</b> , 29, 1681S-1687S	16
586	Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. <b>1995</b> , 17, 622-36	124
585	Zidovudine for the treatment of HIV-negative patients with psoriasis: a pilot study. <b>1995</b> , 32, 994-9	28
584	Rectal bleeding complicating radiofrequency-induced thermal destruction of the endometrium. <b>1995</b> , 172, 1951	4
583	Preventing mother-to-child transmission of human immunodeficiency virus infection. <b>1995</b> , 172, 1952-1953	
582	Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. <b>1995</b> , 38, 2491-517	656
581	Comparison of zidovudine and zidovudine-thymostimulin in the long-term treatment of patients with asymptomatic human immunodeficiency virus infection and persistent generalized lymphadenopathy. <b>1995</b> , 56, 369-384	
580	Time to hit HIV, early and hard. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 450-1	59.2 344
579	Zidovudine therapy in HIV infection: which patients should be treated and when. <b>1995</b> , 40, 107-10	2
578	Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. <b>1995</b> , 25, 344-9	1
577	Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. <b>1995</b> , 374, 165-71	5

576	A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission. <b>1995</b> , 12, 274-82	15
575	The value of the CD4+ count of 500 cells/microliters. <b>1995</b> , 49 Suppl 1, 4-8; discussion 38-40	1
574	Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. <b>1995</b> , 49 Suppl 1, 9-16; discussion 38-40	
573	Combination antiretroviral therapy. Back to the future. <b>1995</b> , 49 Suppl 1, 32-7; discussion 38-40	10
572	The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature. <b>1995</b> , 49, 20-36	10
571	Guidelines for the use of zidovudine in pregnant women with HIV infection. <b>1995</b> , 50, 43-7	3
570	Approach to the HIV-infected child with diarrhea. <b>1995</b> , 6, 17-25	5
569	Antiretroviral therapy. <b>1996</b> , 80, 1263-82	2
568	Hematologic disorders and growth factor support in HIV infection. <b>1996</b> , 10, 1149-61	4
567	The diagnosis and management of HIV infection. <b>1996</b> , 80, 1283-307	5
566	Primary care of the HIV patient: standard practice and new developments in the era of managed care. <b>1996</b> , 80, 375-410	6
565	In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine. <b>1996</b> , 39, 826-33	14
564	Adverse events from drug therapy for human immunodeficiency virus disease. <b>1996</b> , 101, 34-40	60
563	Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. <b>1996</b> , 348, 1547-51	68
562	Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. <b>1996</b> , 348, 283-291	444
561	Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma. <b>1996</b> , 35, 269-70	6
560	Les anti-rétroviraux. <b>1996</b> , 26, 45-52	
559	Methadone maintenance and other factors associated with intraindividual temporal trends in injection-drug use. <b>1996</b> , 13, 241-8	18

558	The pharmacology of zidovudine. <b>1996</b> , 3, 58-62	4
557	Surrogate end points in clinical trials: are we being misled?. <b>1996</b> , 125, 605-13	1089
556	Treatment of HIV infection and its complications. <b>1996</b> , 17, 647-63	
555	Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. <b>1996</b> , 15, 176-87	16
554	Clinical pharmacokinetics of zidovudine. An update. <b>1996</b> , 30, 251-62	57
553	Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships. <b>1996</b> , 30, 314-27	28
552	Current controversies in the treatment of HIV infection and AIDS. An economic perspective. <b>1996</b> , 10, 105-8	4
551	Combination antiretroviral therapy in HIV infection. An economic perspective. <b>1996</b> , 10, 109-13	62
550	In vitro effects of 3'-azido-3'-deoxythymidine (AZT) on normal human polymorphonuclear cell and monocyte-macrophage functional capacities. <b>1996</b> , 18, 161-78	5
549	Extent of Undiagnosed HIV Infection in Hospitalized Patients: Assessment by Linkage of Seroprevalence and Surveillance Methods. <b>1996</b> , 12, 195-202	8
548	2.3 HIV and intermediate immune deficiency. <b>1996</b> , 164, 109-110	
547	4.1 Antiretroviral therapies for HIV. <b>1996</b> , 164, 290-295	7
546	Age-specific HIV incidence among homosexually active men in Australia. <b>1996</b> , 164, 715-8	10
545	Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines. <b>1996</b> , 40, 161-5	15
544	Survivor treatment selection bias in observational studies: examples from the AIDS literature. <b>1996</b> , 124, 999-1005	117
543	Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. <b>1996</b> , 40, 527-40	107
542	Bias in the analysis and reporting of randomized controlled trials. <b>1996</b> , 12, 264-75	34
541	Economic evaluation of HIV testing among intravenous drug users. An analytic framework and its application to Italy. <b>1996</b> , 12, 336-57	10

540	HIV testing and counseling. <b>1996</b> , 8, 177-184	1
539	Pharmacologic considerations for antiviral drug development. <b>1996</b> , 30, 972-7	3
538	Viral dynamics of HIV: implications for drug development and therapeutic strategies. <b>1996</b> , 124, 984-94	146
537	Partner notification program and possibility of including it in the HIV prevention strategies in Japan. <b>1996</b> , 6, 158-65	2
536	A model for treatment strategy in the chemotherapy of AIDS. <b>1996</b> , 58, 367-390	94
535	Clinical toxicity of antiretroviral nucleoside analogs. <b>1996</b> , 31, 121-35	43
534	A cost-benefit analysis of voluntary routine HIV-antibody testing for hospital patients. <b>1996</b> , 42, 1259-72	17
533	Anti-V3 loop spectrotpe in HIV-infected individuals during zidovudine therapy. <b>1996</b> , 24, 227-33	2
532	Human immunodeficiency virus testing and counseling: nuts and bolts. <b>1996</b> , 175, 1502-10	5
531	Transfusion-transmitted disease. <b>1996</b> , 9, 369-94	12
530	Problems of using modelling in the economic evaluation of health care. <b>1996</b> , 5, 1-11	123
529	Statistical analysis of zidovudine (AZT) effect on CD4 cell counts in HIV disease. <b>1996</b> , 15, 75-92	13
528	Analysis of uncontrolled treatment changes in HIV clinical trails. <b>1996</b> , 15, 2053-67	2
527	Use of observational data, including surveillance studies, for evaluating AIDS therapies. <b>1996</b> , 15, 2273-88	5
526	Non-parametric inference of a failure time distribution when the failure times are estimated. <b>1996</b> , 15, 2475-90	
525	Estimation, Testing and Adjustment of Transient Healthy Entrant Effects. <b>1996</b> , 38, 241-254	
524	A model for treatment strategy in the chemotherapy of AIDS. <b>1996</b> , 58, 376-90	18
523	Psychosocial aspects of antiretroviral medication use among HIV patients. <b>1996</b> , 29, 207-19	48

522	The impact of zidovudine (AZT) therapy on the survivability of those with the progressive HIV infection. <b>1996</b> , 23, 1-14		1
521	Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group. <b>1996</b> , 32, 123-31		16
520	Intérêt de l'analyse en cytométrie en flux des sous-populations lymphocytaires chez les patients infectés par le VIH. <b>1996</b> , 1996, 53-57		
519	A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 1081-90	59.2	777
518	Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus. <b>1996</b> , 23, 15-27		20
517	Ups and downs--and ups in the antiviral therapy of HIV infection. <b>1996</b> , 72, 2-5		1
516	Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. <b>1996</b> , 49-68		
515	Quantitation of 3'-amino-3'-deoxythymidine (AMT), a toxic catabolite of 3'-azido-3'-deoxythymidine (AZT), by competitive ELISA. <b>1996</b> , 17, 175-93		2
514	Gender and ethnic differences in survival in a cohort of HIV positive clients. <b>1996</b> , 1, 77-85		9
513	Cost-effectiveness of HIV Screening in Acute Care Settings. <b>1996</b> , 156, 394		33
512	Safety and Efficacy of Lamivudine-Zidovudine Combination Therapy in Zidovudine-Experienced Patients. <b>1996</b> , 276, 111		65
511	Survival From Early, Intermediate, and Late Stages of HIV Infection. <b>1996</b> , 275, 1329		50
510	The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. <b>1996</b> , 143-149		
509	Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection. <b>1996</b> , 156, 169		7
508	Combination therapies against HIV-1 infection: exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals. <b>1996</b> , 10, 357-61		3
507	The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy. <b>1996</b> , 12, 969-75		2
506	Comparative pharmacokinetics of zidovudine and its toxic catabolite 3'-amino-3'-deoxythymidine in HIV-infected patients. <b>1996</b> , 12, 229-33		9
505	Herpesvirus vector-mediated gene delivery to human monocytes. <b>1996</b> , 7, 1331-8		5

504	Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 701-6	59.2	407
503	Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. <b>1996</b> , 173, 1354-66		75
502	Early initiation of antiretroviral therapy for infection with human immunodeficiency virus: considerations in 1996. <b>1996</b> , 23, 227-30		1
501	Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from patient populations in trials of human immunodeficiency virus infection. <b>1996</b> , 144, 1074-85		28
500	Making drugs work against HIV. <b>1996</b> , 31, 11, 15-6		
499	Combined therapy with zidovudine, recombinant granulocyte colony stimulating factors and erythropoietin in asymptomatic HIV patients. <b>1996</b> , 8, 63-6		12
498	Drug discovery for human immunodeficiency virus infection: conquests and hurdles. <b>1996</b> , 37 Suppl B, 151-9		11
497	Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. <b>1996</b> , 173, 849-56		20
496	The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 1091-8	59.2	440
495	Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 426-31	59.2	645
494	Clinical trials. <b>1996</b> , 4, 251-68		3
493	An approach to the validation of markers for use in AIDS clinical trials. <b>1997</b> , 24, 764-74		59
492	A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. <b>1997</b> , 175, 255-64		6
491	Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. <b>1997</b> , 53-70		1
490	Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study. <b>1997</b> , 11, 461-7		12
489	Semiparametric Efficiency and its Implication on the Design and Analysis of Group-Sequential Studies. <b>1997</b> , 92, 1342-1350		120
488	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. <b>1997</b> , 26, 400-7		65
487	HIV/AIDS care giving physicians: their experience and practice patterns. <b>1997</b> , 8, 570-5		3



486	Anti-HIV Activities of Anionic Metalloporphyrins and Related Compounds. <b>1997</b> , 8, 85-97	27
485	Pharmacotherapy of HIV dementia. <b>1997</b> , 31, 457-73	22
484	Twenty-one years of haemophilia. <b>1997</b> , 3 Suppl 1, 17-39	
483	Valproic Acid Increases Cerebrospinal Fluid Zidovudine Levels in a Patient With AIDS. <b>1997</b> , 313, 244-246	2
482	Kaposi's sarcoma and its management in AIDS patients. Recommendations from a Scandinavian Study Group. <b>1997</b> , 29, 3-12	5
481	Has the rate of progression to AIDS changed in recent years?. <b>1997</b> , 11, 1611-8	13
480	Health psychology in the 21st century: Acquired Immunodeficiency Syndrome as a harbinger of things to come. <b>1997</b> , 18, 13-35	1
479	From probability to proof: The respective roles of scientific reviews and the non-scientific press in the publicizing of medical research and its clinical applications. <b>1997</b> , 5, 59-63	
478	Assessing the Effects of Interventions Using Longitudinal Data with Samples Subject to Selection. <b>1997</b> , 53, 924	2
477	Antiretroviral agents. Current usage. <b>1997</b> , 15, 319-29	7
476	EARLY SIGNS AND SYMPTOMS OF HIV INFECTION IN AN ALLERGY PRACTICE. <b>1997</b> , 17, 185-194	
475	Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. <b>1997</b> , 81, 449-70	111
474	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. <b>1997</b> , 32, 194-209	206
473	The HIV global pandemic: the development and emerging implication. <b>1997</b> , 3 Suppl 1, S1-6	5
472	Management of Asymptomatic HIV Infection. <b>1997</b> , 1, 105-117	
471	New horizons: antiretroviral therapy in 1997. <b>1997</b> , 8, 26-38	17
470	Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. <b>1997</b> , 8, 99-116	
469	Current antiretroviral therapy in the treatment of HIV infection. <b>1997</b> , 16, 224-34	6

468 Les traitements antirétroviraux. **1997**, 27, 23-30

467 Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. **1997**, 41, 1143-5 2

466 Markers, cofactors and staging systems in the study of HIV disease progression: a review. **1997**, 92, 437-57 2

465 Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection. **1997**, 22, 109-17 11

464 Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). **1997**, 6, 481-93 418

463 Understanding drug resistance for monotherapy treatment of HIV infection. **1997**, 59, 763-85 41

462 Zidovudine Adherence in Persons with AIDS: The Relation of Patient Beliefs About Medication to Self-Termination of Therapy. **1997**, 12, 216-223 1

461 Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group. **1997**, 16, 135-42 6

460 Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. **1997**, 18, 305-22 32

459 Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy. **1997**, 12, 216-23 40

458 Understanding drug resistance for monotherapy treatment of HIV infection. **1997**, 59, 763-785 1

457 Estimating the proportion of treatment effect explained by a surrogate marker. **1997**, 16, 1515-27 377

456 A graphical assessment of the potential impact of losses to follow-up on the validity of study results. The Terry Bein Community Programs for Clinical Research on AIDS. **1997**, 16, 1943-54 12

455 Meta-analysis for the evaluation of potential surrogate markers. **1997**, 16, 1965-82 218

454 Frequency and determinants of use of antiretroviral and prophylactic therapies against *Pneumocystis carinii* Pneumonia (PCP) before AIDS diagnosis in Italy. **1998**, 14, 41-7 6

453 Proposed CD4(+) T-cell criteria for staging human immunodeficiency virus-infected Chinese adults. **1998**, 89, 11-22 12

452 An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. **1998**, 19, 555-68 21

451 L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). **1998**, 39, 101-11 51

450	Estimating the effect of zidovudine on Kaposi's sarcoma from observational data using a rank preserving structural failure-time model. <b>1998</b> , 17, 1073-102	26
449	A comparison of smoothing techniques for CD4 data measured with error in a time-dependent Cox proportional hazards model. <b>1998</b> , 17, 2061-77	53
448	Statistical issues for HIV surrogate endpoints: point/counterpoint. <b>1998</b> , 17, 2435-2462	33
447	Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients. <b>1998</b> , 55, 138-46	6
446	The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison. <b>1998</b> , 101, 632-7	7
445	HIV/AIDS treatment: lessons from the tuberculosis experience. <b>1998</b> , 1, 157-60	3
444	Human immunodeficiency virus (HIV) in America, 1981 to 1997: epidemiologic and therapeutic considerations. <b>1998</b> , 19, 122-7	4
443	Advances in antiviral therapy in dermatology. <b>1998</b> , 16, 409-19	6
442	Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. <b>1998</b> , 55, 383-404	30
441	AIDS Dementia Complex Diagnosis and Drug Treatment Options. <b>1998</b> , 9, 31-40	3
440	Effect of an explicit decision-support tool on decisions to prescribe antibiotics for sore throat. <b>1998</b> , 18, 220-8	44
439	Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. <b>1998</b> , 27, 908-9	19
438	Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. <b>1998</b> , 279, 35-40	157
437	Antiretroviral Drug Development and Information on the Internet. <b>1998</b> , 2, 141-151	
436	Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. <b>1998</b> , 279, 450-4	637
435	Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. <b>1998</b> , 279, 281-6	418
434	Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. <b>1998</b> , 12, 2031-9	42
433	Detection of HIV-Gag p24-specific antibodies in sera and saliva of HIV-1-infected adults and in sera of infants born to HIV-1-infected mothers. <b>1998</b> , 42, 305-11	8

432	Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. <b>1998</b> , 12, 1259-1265	1
431	Imidazo[1,5-b]pyridazine-d4T conjugates: synthesis and anti-human immunodeficiency virus evaluation. <b>1998</b> , 9, 205-23	15
430	Fetal, infant, and maternal toxicity of zidovudine (azidothymidine) administered throughout pregnancy in <i>Macaca nemestrina</i> . <b>1998</b> , 18, 27-38	19
429	Drugs for AIDS/HIV: assessing the evidence. <b>1998</b> , 14, 567-72	
428	A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. <b>1998</b> , 19, 339-49	52
427	Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. <b>1998</b> , 12, 1983-90	15
426	CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. <b>1998</b> , 12, 1823-32	51
425	Raising the consciousness for identifying and controlling viral STDs: fears and frustrations--Thomas Parran Award Lecture. <b>1998</b> , 25, 58-69	19
424	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. The Italian Seroconversion Study. <b>1998</b> , 121, 369-76	12
423	Effect of Relapse to High-Risk Behavior on the Costs and Benefits of a Program to Screen Women for Human Immunodeficiency Virus. <b>1998</b> , 28, 52-74	5
422	The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. <b>1998</b> , 28, 34-51	5
421	A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. <b>1998</b> , 18, S93-105	39
420	Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. <b>1998</b> , 42, 808-12	39
419	Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. <b>1998</b> , 42, 821-6	6
418	Applications of multiple imputation in medical studies: from AIDS to NHANES. <b>1999</b> , 8, 17-36	193
417	Are HIV-infected patients with rapid CD4 cell decline a subgroup who benefit from early antiretroviral therapy?. <b>1999</b> , 43, 379-88	2
416	Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. <b>1999</b> , 29, 19-34	40
415	Health care providers' influence on HIV-infected women's beliefs and intentions related to AZT therapy. <b>1999</b> , 8, 336-54	10

414	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. <b>1999</b> , 1, 32-9	9
413	Strategies for cohort sampling under the Cox proportional hazards model, application to an AIDS clinical trial. <b>1999</b> , 5, 149-72	14
412	Assessing effects on long-term survival after early termination of randomized trials. <b>1999</b> , 5, 55-66	1
411	Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. <b>1999</b> , 39, 165-182	15
410	Data and safety monitoring in the Concorde and Alpha trials. <b>1999</b> , 20, 207-28	10
409	Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. <b>1999</b> , 26, 309-17	109
408	Is the AIDS incubation time changing? A back-calculation approach. <b>1999</b> , 18, 1031-47	4
407	Enumeration of CD4(+) T-cells in the peripheral blood of HIV-infected patients: an interlaboratory study of the FACSCount system. <b>1999</b> , 38, 231-7	25
406	Partner notification as a prevention strategy: a social system perspective. <b>1999</b> , 13, 327-34	1
405	Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. <b>1999</b> , 353, 2014-2025	38
404	Modeling economic evaluations of pharmaceuticals: manipulation or valuable tool?. <b>1999</b> , 21, 896-908; discussion 895	3
403	Combined antiviral treatment in HIV infection. Is it value for money?. <b>1999</b> , 113, 315-7	7
402	Antiretrovirals. <b>1999</b> , 74, 1284-301	20
401	A risk-benefit assessment of HIV protease inhibitors. <b>1999</b> , 20, 299-321	31
400	The use of combination antiretroviral therapy in HIV-infected patients. <b>1999</b> , 33, 198-209	12
399	Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. <b>1999</b> , 21, 326-32	47
398	Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. <b>1999</b> , 13, 2157-64	34
397	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. <b>1999</b> , 13, 2377-88	35

396	HIV therapeutics: Past, present, and future. <b>2000</b> , 49, 1-40	
395	Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. <b>2000</b> , 160, 1123-32	181
394	Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. <b>2000</b> , 133, 464-70	223
393	Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1 Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy. <b>2000</b> , 23, 26-34	7
392	Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. <b>2000</b> , 24, 316-24	60
391	Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy. <b>2000</b> , 18, 118-24	21
390	Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. <b>2000</b> , 23, 26-34	32
389	Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. <b>2000</b> , 14, 197-201	47
388	Analyses of quality assessment studies using CD45 for gating lymphocytes for CD3(+)4(+)% . <b>2000</b> , 42, 1-4	26
387	Anorectal lymphoma and AIDS: an outcome analysis. <b>2000</b> , 73, 1-4; discussion 4-5	13
386	Commentary. <b>2000</b> , 73, 4-5	
385	[Antiretroviral therapy of HIV-infections]. <b>2000</b> , 29, 284-96	0
384	A review of antiretroviral drugs. <b>2000</b> , 13, 305-317	5
383	A mixture model for longitudinal data with application to assessment of noncompliance. <b>2000</b> , 56, 464-72	39
382	A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia. <b>2000</b> , 30, 11-20	7
381	Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults. <b>2000</b> , CD002039	7
380	Management of the adverse effects of antiretroviral therapy and medication adherence. <b>2000</b> , 30 Suppl 2, S96-116	148
379	Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV Infection. <b>2000</b> , 24, 316-324	62

378	The implementation of the DHHS guidelines for the use of antiretroviral agents in HIV-infected adults: a pilot study. <b>2000</b> , 12, 187-92	1
377	Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. <b>2000</b> , 16, 1031-7	12
376	In vivo antagonism with zidovudine plus stavudine combination therapy. <b>2000</b> , 182, 321-5	78
375	Development of a novel (32)P-postlabeling method for the analysis of 3'-azido-3'-deoxythymidine. <b>2000</b> , 153, 25-33	4
374	Evaluating the outcome of treatment. Shouldn't We be asking patients if they are better?. <b>2000</b> , 53, 549-53	72
373	Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland. <b>2001</b> , 37, 340-70	83
372	Advances in HIV treatment and treatment toxicities. <b>2001</b> , 19, 757-72	3
371	Statistical issues relating to international differences in clinical trials. <b>2001</b> , 142, 21-8	17
370	Patterns of patient enrollment in randomized controlled trials. <b>2001</b> , 54, 877-83	73
369	Mechanical cardiac support 2000: current applications and future trial design. <b>2001</b> , 20, 1-38	23
368	Actualizaci3n en el tratamiento de la infecci3n VIH. Inter3s para el dermat3logo. <b>2001</b> , 92, 1-8	
367	Understanding clinical trials in pain research. <b>2001</b> , 568-582	
366	Multinomial analysis of smoothed HIV back-calculation models incorporating uncertainty in the AIDS incidence. <b>2001</b> , 20, 2017-33	7
365	Less is more? STI in acute and chronic HIV-1 infection. <b>2001</b> , 7, 881-4	42
364	Drugs and cardiotoxicity in HIV and AIDS. <b>2001</b> , 946, 179-99	49
363	Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. <b>2001</b> , 84, 230-6	20
362	Nucleoside Reverse Transcriptase Inhibitor Resistance. <b>2001</b> , 26, S10-S24	33
361	International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. <b>2001</b> , 26 Suppl 1, S10-24	26

360 Antiviral Treatments. **2001**, 316-341

- 359 Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. **2001**, 47, 371-5 14
- 358 Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence. **2002**, 13, 748-54 21
- 357 Women and AIDS. **2002**,
- 356 Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. **2002**, 324, 757 56
- 355 Innovative Therapies, Suspended Trials, and the Economics of Clinical Research: Facilitated Communication and Biomedical Cases. **2002**, 32, 275-309 3
- 354 Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count  $> 350 \times 10^6 /l$ . **2002**, 16, 1371-81 80
- 353 The changing face of HIV. **2002**, 14, 1-7
- 352 Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. **2002**, 16, 405-11 42
- 351 Differentiation and treatment of anemia in HIV disease. **2002**, 13, 47-68; quiz 69-72 3
- 350 Current strategies in the treatment of HIV infection. **2002**, 48, A3-184 2
- 349 Antivirals against HIV-1. **2002**, 22, 741-57, vii 2
- 348 Epidemiology, Manifestations, and Treatment of HIV Infection in Women. **2002**, 1-32 1
- 347 Statistical challenges in the evaluation of surrogate endpoints in randomized trials. **2002**, 23, 607-25 95
- 346 Resource allocation for HIV/AIDS control programs: a model-based policy analysis. **2002**, 24, 99-124 12
- 345 Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. **2002**, 21, 1689-709 215
- 344 Non-linear hierarchical models for monitoring compliance. **2002**, 21, 219-29 7
- 343 Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data. **2002**, 58, 37-47 42



342	Structure-based design of AIDS drugs and the development of resistance. <b>2002</b> , 83 Suppl 1, 23-6	9
341	Rational approach to AIDS drug design through structural biology. <b>2002</b> , 53, 595-614	124
340	Modulation of apoptosis by HIV protease inhibitors. <b>2002</b> , 7, 295-312	23
339	The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition. <b>2003</b> , 28, 383-412	24
338	A flow cytometric method for enumeration of lymphocyte sub-populations in sample containing lysis-resistant red blood cells. <b>2003</b> , 86, 259-64	1
337	Patterns of antiretroviral use in the United States of America: analysis of three observational databases. <b>2003</b> , 4, 24-32	31
336	Clinical trials of antiretroviral drugs: the role of the MRC AIDS Therapeutic Trials Committee (ATTC) and the MRC Clinical Trials Unit (CTU). <b>2003</b> , 55, 469-72	1
335	Late-starter sites in randomized controlled trials. <b>2003</b> , 56, 408-15	11
334	Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. <b>2003</b> , 4, 537-47	111
333	Multivariable analysis: a primer for readers of medical research. <b>2003</b> , 138, 644-50	231
332	Vaccine Protocols. <b>2003</b> ,	6
331	Managing the care of patients infected with bloodborne diseases. <b>2003</b> , 134, 350-8	18
330	HIV therapy in 2003: consensus and controversy. <b>2003</b> , 17 Suppl 1, S4-11	27
329	[German-Austrian guidelines for antiretroviral therapy of HIV infection. (July, 2002, update)]. <b>2003</b> , 128 Suppl 1, S7-18	5
328	Clinical trials. <b>2003</b> , 87, 335-52	0
327	Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[troviridine analogue] of known HIV-1 reverse transcriptase inhibitors. <b>2003</b> , 18, 175-86	8
326	Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. <b>2003</b> , 1, 131-52	36
325	Progression of HIV disease among women following delivery. <b>2003</b> , 33, 585-93	52

324	Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1. <b>2003</b> , 33, 343-8	2
323	Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production. <b>2004</b> , 23, 173-85	13
322	Synthesis and anti-HIV activity of some [Nucleoside Reverse Transcriptase Inhibitor]-C5'-linker-[Integrase Inhibitor] heterodimers as inhibitors of HIV replication. <b>2004</b> , 19, 497-509	3
321	Therapy of HIV infection. <b>2004</b> , 17, 449-64	3
320	Safety of hydroxyurea in the treatment of HIV infection. <b>2004</b> , 3, 279-88	14
319	Antiretroviral Chemotherapy. <b>2004</b> , 841-854	
318	Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. <b>2004</b> , 116 Suppl 7A, 27S-43S	185
317	The placebo (I shall please)--is it so pleasing in children?. <b>2005</b> , 15, 809-13	16
316	Initiating and changing antiretroviral therapy. <b>2005</b> , 355-376	
315	Contradicted and initially stronger effects in highly cited clinical research. <b>2005</b> , 294, 218-28	890
314	Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. <b>2005</b> , 21, 263-72	10
313	Regression Methods in Biostatistics. <b>2005</b> ,	
312	Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. <b>2005</b> , 19, 1173-81	24
311	A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. <b>2006</b> , 24, 751-65	100
310	Surrogate Markers. <b>2006</b> ,	
309	Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. <b>2006</b> , 8, 16	1
308	Survival analysis using auxiliary variables via non-parametric multiple imputation. <b>2006</b> , 25, 3503-17	43
307	Impact of highly active antiretroviral therapy on outcome of cholecystectomy in patients with human immunodeficiency virus infection. <b>2006</b> , 93, 1383-9	14

306	Effects of antiretroviral therapy on immunity in patients infected with HIV. <b>2006</b> , 12, 1015-22	6
305	Millions of life-years saved with potent antiretroviral drugs in the United States: a celebration, with challenges. <b>2006</b> , 194, 1-5	14
304	Combination exposure to zidovudine plus sulfamethoxazole-trimethoprim diminishes B-lymphocyte immune responses to <i>Pneumocystis murina</i> infection in healthy mice. <b>2006</b> , 13, 193-201	4
303	HIV and other lentiviral infections cause defects in neutrophil chemotaxis, recruitment, and cell structure: immunorestorative effects of granulocyte-macrophage colony-stimulating factor. <b>2006</b> , 177, 6405-14	30
302	Vitamin C prevents zidovudine-induced NAD(P)H oxidase activation and hypertension in the rat. <b>2007</b> , 73, 432-8	36
301	Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. <b>2007</b> , 51, 3516-22	22
300	Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. <b>2007</b> , 76, 132-8	40
299	Neuropharmacology of HIV/AIDS. <b>2007</b> , 85, 319-64	
298	Management of acromegaly: is there a role for primary medical therapy?. <b>2008</b> , 9, 83-94	28
297	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. <b>2008</b> , 28, 886-94	42
296	Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. <b>1992</b> , 88, 243-52	157
295	The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. <b>1992</b> , 90, 376-82	129
294	The incidence of HIV-related disease in a cohort of haemophilic men: natural history and changes since the introduction of pre-AIDS treatment. <b>2008</b> , 15, 241-251	1
293	Planning for closeout--from Day One. <b>2008</b> , 29, 136-9	8
292	Other potential medical therapies: the use of antiviral agents to investigate and treat primary ciliary cirrhosis. <b>2008</b> , 12, 445-60; xi	13
291	Scientific Errors and Controversies in the U.S. HIV/AIDS Epidemic: How They Slowed Advances and Were Resolved:Scientific Errors and Controversies in the U.S. HIV/AIDS Epidemic: How They Slowed Advances and Were Resolved. <b>2009</b> , 48, 999-1000	1
290	Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. <b>2009</b> , 23, 203-12	13
289	Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. <b>2009</b> , 18, 709-25	73

288 :Therapeutic Microbiology. **2009**, 48, 1000-1001

287	Ophthalmic disease in patients with unrecognized HIV infection. <b>1993</b> , 71, 662-5	1
286	Study of the role of vitamin B12 and folic acid supplementation in preventing hematologic toxicity of zidovudine. <b>1995</b> , 55, 97-102	19
285	HIV/AIDS Drugs. 75-101	
284	Nonparametric comparison of two survival functions with dependent censoring via nonparametric multiple imputation. <b>2009</b> , 28, 462-75	12
283	Median regression models for longitudinal data with dropouts. <b>2009</b> , 65, 618-25	45
282	Clozapine Use in HIV-Infected Schizophrenia Patients: A Case-Based Discussion and Review. <b>2009</b> , 50, 626-632	11
281	Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric backcalculation method. <b>2009</b> , 23, 1143-52	20
280	CD4 counts in patients diagnosed with HIV through routine HIV screening in two urban emergency departments. <b>2010</b> , 54, e15-6	1
279	Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. <b>2010</b> , 54, e13-4	10
278	No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla. <b>2010</b> , 54, e12-3	2
277	When to start antiretroviral therapy. <b>2010</b> , 7, 60-8	25
276	Linking human beta retrovirus infection with primary biliary cirrhosis. <b>2010</b> , 34, 359-66	18
275	Assessing the extent of the Australian HIV epidemic from AIDS surveillance data. <b>1993</b> , 17, 226-31	8
274	Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. <b>2010</b> , 13, 42	29
273	A controlled neuropsychological study of HIV-seropositive and HIV-seronegative adolescent haemophiliacs. <b>1996</b> , 2, 145-52	4
272	Surrogate Markers. <b>2010</b> , 1	
271	A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. <b>2010</b> , 19, 205-36	16

270	Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. <b>2010</b> , 51, 600-8	29
269	HIV/AIDS 2010: Better drugs, better technologies, and lingering problems. <b>2010</b> , 170, 6-8	2
268	The development of combination therapies for HIV infection. <b>2010</b> , 26, 501-9	3
267	Tolerability of HAART in patients treated during acute HIV infection. <b>2010</b> , 54, e11-2	1
266	How long is the right interval for assessing antiretroviral pharmacy refill adherence?. <b>2010</b> , 54, e16-8	9
265	Efficacy and tolerability of zidovudine 200 mg twice a day as part of combination antiretroviral therapy for 96 weeks. <b>2010</b> , 54, e19-20	2
264	Human Retroviral Infections in the Tropics. <b>2011</b> , 541-558	
263	Outcome variables in multivariable analysis. 25-73	
262	CD4 lymphocyte count as predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs. <b>2011</b> , 1, 210-211	2
261	Statistical decisions and the interim analyses of clinical trials. <b>2011</b> , 32, 61-74	3
260	When to start antiretroviral therapy. <b>2011</b> , 13, 60-7	3
259	Daily quality control in CD3+ and CD4+ T cell estimation by the FACSCount system at a tertiary care center in south India. <b>2012</b> , 19, 1693-6	3
258	The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. <b>2012</b> , 26, 1231-41	95
257	Letter to the Editor. <b>2012</b> , 15, 1328-1328	
256	References. <b>2012</b> , 223-241	
255	Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. <b>2012</b> , 12, 550-60	32
254	Survival Analysis. <b>2012</b> , 203-259	3
253	Regression Methods in Biostatistics. <b>2012</b> ,	238

- 252 Bias corrected estimation for generalized probit regression with covariate measurement error and censored responses. **2012**, 142, 221-231
- 251 An update on oxidative stress-mediated organ pathophysiology. **2013**, 62, 584-600 97
- 250 Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. **2013**, 13, 522 13
- 249 Trials challenging HIV drug doses could usher in huge cost cuts. **2013**, 19, 953 1
- 248 Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries. **2013**, 18, 40-4 5
- 247 Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children. **2013**, 57, 4801-8 6
- 246 Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine). **2013**, 102, 2409-23 6
- 245 AN EMPIRICAL MODEL OF LEARNING UNDER AMBIGUITY: THE CASE OF CLINICAL TRIALS\*. **2013**, 54, 549-573 6
- 244 Surrogate Markers. **2014**,
- 243 Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. **2015**, 70, 1139-45 19
- 242 Partial marginal likelihood estimation for general transformation models. **2014**, 123, 1-18
- 241 Graphical Approaches to Multiple Testing. **2014**, 385-430
- 240 Adaptive Clinical Trial Designs with Biomarker Development and Validation. **2015**, 313-332 1
- 239 Zidovudine. **2015**, 32, 76-77
- 238 Surrogate Markers. **2015**, 1-24
- 237 A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey. **2015**, 6, 55-64 7
- 236 General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases). **2015**, 1541-1557.e5<sup>2</sup>
- 235 Antiretroviral Therapy for Human Immunodeficiency Virus Infection. **2015**, 1622-1641.e6 2

234	Not all RCTs are created equal: lessons from early AIDS trials. <b>2015</b> , 15, 45-7	6
233	The Human Immunodeficiency Virus. <b>2016</b> , 39-54	
232	Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC). <b>2016</b> , 49, 2091-2098	18
231	A Historical Overview of the Epidemiology of HIV/AIDS in the United States. <b>2016</b> , 19-41	1
230	Translational Pharmacology in Glaucoma Neuroprotection. <b>2017</b> , 242, 209-230	6
229	Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity. <b>2016</b> , 24, 406-415	3
228	Efficient quantile marginal regression for longitudinal data with dropouts. <b>2016</b> , 17, 561-75	9
227	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <b>2016</b> , 58, 104-32	54
226	Backbones versus core agents in initial ART regimens: one game, two players. <b>2016</b> , 71, 856-61	14
225	Drugs for HIV Infection. <b>2017</b> , 1293-1308.e2	8
224	Thirty-five years of CD4 T-cell counting in HIV infection: From flow cytometry in the lab to point-of-care testing in the field. <b>2017</b> , 92, 437-444	10
223	How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know. <b>2018</b> , 15, 359-365	11
222	Drug repurposing from the perspective of pharmaceutical companies. <b>2018</b> , 175, 168-180	155
221	Chagas Disease. <b>2019</b> ,	6
220	Data Monitoring Committee Meetings. <b>2019</b> , 203-236	
219	Statistical, Philosophical, and Ethical Issues in Data Monitoring. <b>2019</b> , 265-334	1
218	In Silico Drug Design Methods for Drug Repurposing. <b>2019</b> , 47-84	6
217	Drug-drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs. <b>2019</b> , 24, 287-312	20

216	Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches. <b>2021</b> , 16, 113-129	8
215	AZT oxidative damage in the liver. <b>2021</b> , 297-304	
214	HIV/AIDS in Thailand. <b>2004</b> , 3-33	3
213	Quality-of-life assessment in clinical trials. <b>1995</b> , 75, 225-46	10
212	Issues in the design and analysis of AIDS clinical trials. <b>1995</b> , 75, 29-47	1
211	Central Nervous System Infection in the Immunocompromised Host. <b>1994</b> , 163-210	1
210	Lipophilic 6-Halo-2',3'-Dideoxypurine Nucleosides: Potential Antiretroviral Agents Targeting HIV-Associated Neurologic Disorders. <b>1991</b> , 323-333	6
209	Perspectives on Using Backcalculation to Estimate HIV Prevalence and Project AIDS Incidence. <b>1992</b> , 1-38	11
208	Is Earlier Better for AZT Therapy in HIV Infection? A Mathematical Model. <b>1992</b> , 366-383	3
207	Efficacy of combination antiretroviral therapy. <b>1996</b> , 394, 355-72	10
206	Behavioral Interventions for In-Treatment Injection Drug Users. <b>1994</b> , 189-208	2
205	Interventions for Sexual Partners of HIV-Infected or High-Risk Individuals. <b>1994</b> , 227-242	1
204	The Simian Retroviruses SIV and SRV. <b>1994</b> , 133-276	27
203	Delavirdine. <b>2006</b> , 375-400	1
202	Zidovudine, Lamivudine, and Abacavir. <b>2006</b> , 33-76	2
201	Deutsch-Österreichische Richtlinien zur Antiretroviralen Therapie der HIV-Infektion. <b>2000</b> , 881-891	0
200	Selection of zidovudine-resistant variants of human immunodeficiency virus by therapy. <b>1992</b> , 176, 131-42	7
199	Monitoring of disease progression of HIV infection. <b>1992</b> , 91-111	1



198	Infectious Diseases. <b>1993</b> , 301-339	4
197	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including the Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases). <b>2010</b> , 1705-1725	2
196	The Impact of Antiviral Therapy on HIV Disease. <b>1999</b> , 189-206	2
195	Quantitative Science. <b>2005</b> , 58-89	1
194	The Evolution of Comprehensive AIDS Clinical Care. <b>2005</b> , 261-285	1
193	Reduction of 3Bzido-3Bdeoxythymidine (AZT) and AZT nucleotides by thiols. Kinetics and product identification.. <b>1994</b> , 269, 15999-16008	20
192	The Epidemiology of the Acquired Immunodeficiency Syndrome in the 1990s. <b>1995</b> , 13, 1-25	21
191	Acquired Immunodeficiency Syndrome. <b>1990</b> , 8, 771-786	5
190	Future Therapies in the Management of Critically Ill, AIDS Patients. <b>1993</b> , 9, 153-176	4
189	Preventive Care Among HIV-Positive Patients in a General Medicine Practice. <b>1994</b> , 10, 5-9	13
188	THERAPY FOR HEPATITIS B VIRUS INFECTION. <b>1994</b> , 23, 581-601	23
187	HEPATOTOXICITY OF ANTIVIRAL AGENTS. <b>1995</b> , 24, 839-852	6
186	The Use of Hematopoietic Hormones in HIV Infection and AIDS-Related Malignancies. <b>1991</b> , 5, 267-280	9
185	IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION ON WOMEN AND INFANTS. <b>1992</b> , 6, 1-17	6
184	PERSPECTIVES ON THE USE OF ANTIRETROVIRAL DRUGS IN THE TREATMENT OF HIV INFECTION. <b>1994</b> , 8, 303-317	5
183	Hospital-based routine HIV testing programs. <b>1990</b> , 11, 625-7	3
182	Evaluation of a hospital admission HIV antibody voluntary screening program. <b>1990</b> , 11, 628-34	12
181	A world ravaged by a disease without HAART. <b>2008</b> , 7-34	1

180	Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS. <b>1997</b> , 313, 244-6	14
179	Management of HIV infection for the childbearing age woman. <b>1996</b> , 39, 344-60	5
178	The role of antiretroviral therapy in the management of HIV infection in women. <b>1996</b> , 39, 361-85	3
177	The diagnosis and management of perinatal HIV infection. <b>1996</b> , 39, 396-410	4
176	Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. <b>1996</b> , 34, 44-57	111
175	Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. <b>1999</b> , 37, 908-25	50
174	Radioimmunoassay of zidovudine: extended use and potential application. <b>1997</b> , 19, 195-200	12
173	Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. <b>1996</b> , 11, 45-52	5
172	Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. <b>1996</b> , 11, 142-50	14
171	Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. <b>1996</b> , 11, 161-9	34
170	A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. <b>1996</b> , 11, 379-84	31
169	Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV. <b>1996</b> , 11, 469-77	2
168	Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group. <b>1996</b> , 12, 46-55	15
167	Opportunities for targeting publicly funded human immunodeficiency virus counseling and testing. <b>1996</b> , 12, 69-74	26
166	Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease. <b>1996</b> , 12, 153-7	15
165	Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group. <b>1996</b> , 12, 249-58	4
164	Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. <b>1996</b> , 12, 413-20	54
163	A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS. <b>1996</b> , 12, 462-9	7

162	Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. <b>1997</b> , 14, 145-52	26
161	Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. <b>1997</b> , 14, 223-31	40
160	A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. <b>1997</b> , 15, 283-8	8
159	Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. <b>1997</b> , 16, 153-60	45
158	Projected incidence of AIDS in San Francisco: the peak and decline of the epidemic. <b>1997</b> , 16, 182-9	9
157	Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. <b>1997</b> , 16, 247-53	15
156	Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research. <b>1998</b> , 17, 345-53	2
155	Evaluating the cost of medications for ambulatory HIV-infected persons in association with landmark changes in antiretroviral therapy. <b>1998</b> , 17, 354-60	17
154	Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. <b>1998</b> , 42, 358-61	12
153	Determination of CD4 and CD8 lymphocyte subsets by a new alternative fluorescence immunoassay. <b>1995</b> , 2, 330-6	7
152	Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics. <b>1998</b> , 5, 636-44	9
151	Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. <b>1993</b> , 31, 2557-64	46
150	Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. <b>1993</b> , 31, 2960-6	52
149	Enzyme immunoassay for detection of human immunodeficiency virus-specific immunoglobulin A antibodies. <b>1993</b> , 31, 681-4	5
148	Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. <b>1995</b> , 33, 342-7	59
147	Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. <b>1998</b> , 36, 1056-63	6
146	Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. <b>1992</b> , 66, 6587-600	136
145	Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. <b>1995</b> , 69, 3510-6	33

144	Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. <b>1996</b> , 70, 5930-4	93
143	A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. <b>1998</b> , 72, 5093-8	96
142	Pathogenesis of human immunodeficiency virus infection. <b>1993</b> , 57, 183-289	702
141	Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. <b>1994</b> , 308, 1068-73	72
140	Managing HIV disease after Delta. <b>1996</b> , 312, 521-2	11
139	Will we ever know when to treat HIV infection?. <b>1996</b> , 313, 608-10	6
138	AIDS, Homophobia, and Biomedical Discourse. <b>1999</b> , 11-41	1
137	The Burdens of History. <b>1999</b> , 42-98	0
136	Validation of four AIDS-case definitions in HIV-infected intravenous drug users in Barcelona, Spain. <b>1998</b> , 1, 170-176	2
135	Epidemiology of late presentation of HIV infection in Western Australia. <b>1992</b> , 157, 117-118	21
134	The acquired immunodeficiency syndrome in Australia: incidence 1982-1991. <b>1993</b> , 158, 10-7	37
133	Benefits of early diagnosis of HIV infection. <b>1993</b> , 158, 35-6	1
132	Anti-Retroviral Therapy and Resistance to Anti-Retroviral Drugs. <b>2000</b> , 221-242	
131	Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. <b>2001</b> , 85-100	
130	HIV in America, 1981 to 2000: Therapeutic and Epidemiologic Considerations. <b>2001</b> , 9-17	
129	Drugs Targeted at HIV: Successes and Resistance. <b>2002</b> , 269-286	1
128	Cutaneous Virology. <b>2002</b> , 1-24	
127	Deutsch-Österreichische Richtlinien zur Antiretroviralen Therapie der HIV-Infektion (Juli 2002). <b>2003</b> , 59-87	

126 Sektion II Praxis. **2003**, 1-340

125 A perspective of the history of HAART. **2004**, 25-40

124 LABORATORY MARKERS ASSOCIATED WITH PROGRESSION OF HIV INFECTION. **2004**, 22, 7-15 3

123 Antiretroviral Drugs to Treat Human Immunodeficiency Virus Infections. **2004**, 25-122

122 Antiviral Drugs. **2005**, 391-399

121 General Principles of Infection. **2008**, 675-694 0

120 An Empirical Model of Learning Under Ambiguity: The Case of Clinical Trials.

119 Management of HIV Infection. **2008**, 667-675

118 Antiretroviral Therapy for Human Immunodeficiency Virus Infection. **2010**, 1833-1853

117 Antiretroviral therapy for HIV. **2010**, 556-566

116 CD4 T Cell Assessments in Evaluation of HIV Therapeutics. 169-187

115 11 Fertility treatments in human immunodeficiency virus (HIV) infected patients. **2011**,

114 HIV Epidemic. **2013**, 3-46 1

113 General Principles of Infection. **2013**, 706-723.e3 1

112 HIV/AIDS Related Eye Diseases. **2014**, 321-353

111 Status and Current Prospects for the Immunotherapy of Human Immunodeficiency Virus (HIV) Infection. **1990**, 91-107

110 Zur Therapie der HIV-Infektion mit Zidovudine (AZT). **1990**, 530-533

109 AIDS. **1990**, 17, 545-555 3

108 Aids und HIV-Infektion. **1991**, 969-980

107 How Just Must We Be?. **1991**, 131-188

106 The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. **1991**, 2 Suppl 2, 191-200

105 Die antiretrovirale Therapie der HIV-Infektion. **1991**, 56-70

104 AIDS in the Hand Patient: The Team Approach. **1991**, 7, 433-445

7

103 Natural history of HIV infection. **1992**, 1-30

102 Prognostic Indicators for Progression of HIV Disease. **1992**, 143-151

101 Testing for Human Retroviral Infections: Medical Indications and Ethical Considerations. **1992**, 6-17

100 AIDS: The Uses and Limitations of Science. **1992**, 31-48

99 Virustatische Behandlung der HIV-Infektion. **1992**, 15-20

98 Baseline analysis of sociocultural aspects of AIDS: 1982-1991. **1992**, 93-137

97 Health care and medical technology. **1992**, 243-279

96 HIV-assozierte EEG-Befunde der Stadien WR 2B. **1992**, 60-66

95 Acquired Immunodeficiency Syndrome. **1992**, 859-887

94 AIDS-Inzidenz und -Manifestationen bei Hämophilen. Aktuelle Entwicklung unter Zidovudin und Pentamidin-Prophylaxe. **1992**, 48-55

93 Management of Occupational Exposure to the Human Immunodeficiency Virus. **1992**, 197-204

92 Targeting Clinical and Preventive Care to and Around HIV-Infected Persons: The Concept of Early Intervention. **1992**, 254-265

91 EXPANDING ACCESS TO INVESTIGATIONAL NEW THERAPIES. **1992**, 19, 87-96

1

90	PATHOGENESIS, NATURAL HISTORY, AND CLASSIFICATION OF HIV INFECTION. <b>1992</b> , 19, 1-17	0
89	INITIAL CLINICAL ASSESSMENT AND MANAGEMENT OF HIV INFECTION. <b>1992</b> , 19, 35-56	1
88	ANTIVIRAL AGENTS. <b>1992</b> , 19, 563-585	7
87	The Human Immunodeficiency Virus. <b>1992</b> , 25, 1159-1181	2
86	Aids and the CNS: Anesthetic Implications. <b>1993</b> , 103-118	
85	Acquired Immunodeficiency Syndrome (AIDS). <b>1994</b> , 763-780	
84	Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. <b>1994</b> , 286-293	
83	Literaturverzeichnis. <b>1994</b> , 289-322	
82	The ENT Presentation of HIV Infection and the Acquired Immunodeficiency Syndrome. <b>1994</b> , 31-44	
81	Programs for Routine, Voluntary HIV Counseling and Testing of Patients in Acute-Care Hospitals. <b>1994</b> , 245-251	
80	Prognostic Indicators for Progression of HIV Disease. <b>1994</b> , 196-205	1
79	Z. <b>1994</b> , 1227-1253	
78	Malabsorption Syndromes and Intestinal Protein Loss. <b>1994</b> , 457-491	
77	Testing for Human Retrovirus Infections: Medical Indications and Ethical Considerations. <b>1994</b> , 1-14	
76	Human Immunodeficiency Virus. <b>1994</b> , 128-155	
75	Treatment of Viral Infections in the Human Immunodeficiency Virus-Infected Patient. <b>1994</b> , 469-490	
74	Management of Occupational Exposure to HIV. <b>1994</b> , 361-375	1
73	Antiretrovirale Kombinationstherapie bei HIV-1-Infektion und Therapie HIV-assoziierter Komplikationen. <b>1994</b> , 41-46	

- 72 HIV-Infektion und Kaposi-Sarkom. **1995**, 937-986
- 71 AIDS und HIV-Infektion. **1995**, 1196-1209 1
- 70 Noninfectious Manifestations of Human Immunodeficiency Virus Infection. **1995**, 13, 105-131 3
- 69 Management of occupational exposure to HIV. **1995**, 14, 235-9
- 68 AZT toxicity and AIDS prophylaxis: is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter?. **1996**, 131-141
- 67 Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. **1996**, 435-453
- 66 Erfolgreiche Therapie einer HIV1-assoziierten Demenz mit Zidovudin (AZT). **1996**, 123-126
- 65 Ethical Considerations Raised by Clinical Trials. **1996**, 335-349
- 64 Zidovudine: anno 1995. **1996**, 394, 225-43
- 63 The Out-patient Management of HIV Infection. **1996**, 1-18
- 62 Controversies in initiating anti-retroviral therapy and in the use of combination therapies. **1996**, 394, 333-43
- 61 Occurrence of lymphomas during ddC or ddC/zidovudine combination therapy in persons infected with HIV type 1. **1996**, 13, 464-5 2
- 60 Proton Spectroscopy in a Cross-Section of HIV-Positive Asymptomatic Patients Receiving Immediate Compared with Deferred Zidovudine (Concorde Study). **1997**, 1, 103-13 1
- 59 At the Interface of Statistics and Medicine: Conflicting Paradigms. **1997**, 107-134
- 58 How Does Basic Research in Cancer and AIDS Approach the Concern for Quality of Life?. **1997**, 17-35
- 57 The Current Face of the AIDS Epidemic. **1997**, 12-19
- 56 Economic Evaluation of HIV Screening Interventions. **1998**, 81-101 1
- 55 Closeout. **1998**, 323-332



54 Seduced and Terrorized. **1999**, 127-148

53 Epilogue. **1999**, 315-329

52 AIDS, Africa, and Cultural Theory. **1999**, 205-234

51 AIDS, HIV, and the Cultural Construction of Reality. **1999**, 149-175

50 AIDS Narratives on Television. **1999**, 176-204

49 Beyond Cosmo. **1999**, 235-277

48 Initial Treatment for HIV Infection. **1999**, 229-237

47 AIDS and HIV Infection in the Third World. **1999**, 99-126

1

46 How to Have Theory in an Epidemic. **1999**, 278-314

45 Notes. **1999**, 331-386

44 Bibliography. **1999**, 387-451

43 References. 443-629

42 Neurologic Outcomes in HIV Infection: Clinical Events and Surrogate Markers. 95-104

41 Contributions That Mitigated the Epidemic. **2016**, 111-114

40 Chagas Disease in Immunosuppressed Patients. **2019**, 265-296

39 The Bio/Necropolitics of ACTG 076: Lessons from Pregnant Women of Colour Living with HIV for Treatment for Prevention in the Twenty-first Century. **2020**, 10, 233-253

38 The XIV International AIDS Conference: a call for action ... now. **2002**, 167, 483-4

1

37 Counseling patients seropositive for human immunodeficiency virus. An approach for medical practice. **1990**, 153, 629-34

6

36	Zidovudine in the treatment of human immunodeficiency virus disease. <b>1991</b> , 154, 323-4	
35	Prevalence of human immunodeficiency virus infection in a sample of immigrants in the United States. <b>1993</b> , 158, 145-7	1
34	Pseudothrombocytopenia in a child with the acquired immunodeficiency syndrome. <b>1992</b> , 157, 668-70	3
33	Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada. <b>1998</b> , 158, 1449-57	10
32	Anorectal surgery in HIV-seropositive patients. <b>1991</b> , 84, 191-2	
31	Practical issues regarding the use of antiretroviral therapy for HIV infection. <b>1998</b> , 168, 133-9	6
30	Periodic health examination, 1992 update: 3. HIV antibody screening. Canadian Task Force on the Periodic Health Examination. <b>1992</b> , 147, 867-76	1
29	Profile of HIV seropositive inmates diagnosed in Maryland's state correctional system. <b>1994</b> , 109, 756-60	4
28	Zidovudine (Retrovir) update. <b>1990</b> , 143, 1177-85	4
27	Bleak news from the AIDS front. <b>1993</b> , 149, 1016-8	3
26	Current approaches to prevention of HIV infections. <b>1991</b> , 106, 111-5	7
25	Preventing secondary infections among HIV-positive persons. <b>1991</b> , 106, 503-17	2
24	Disease management--constructing optimal NRTI-based combinations: past, present, and future. <b>2006</b> , 8, 16	
23	Early Clinical Signs and Symptoms of HIV Infection: Delaying progression to AIDS. <b>1992</b> , 38, 1401-10	1
22	The renaissance of fixed dose combinations: Combivir. <b>2007</b> , 3, 579-83	11
21	Changing epidemiology of AIDS. <b>1994</b> , 40, 1414-20	
20	Compliance with public sector HIV medical care. <b>1995</b> , 87, 19-24	42
19	Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users. <b>1996</b> , 88, 37-42	6

18	Prevalence, severity, and related factors of anemia in HIV/AIDS patients. <b>2012</b> , 17, 138-42	31
17	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. <b>2008</b> , 13, 959-67	47
16	It was 40 Years Ago Today: AIDS and the Brain.. <b>2022</b> , 36, 682	1
15	The Medication Attribution Scale: perceived effects of antiretrovirals and quality of life. <b>1998</b> , 7, 205-14	5
14	Why there are so many contradicted or exaggerated findings in highly-cited clinical research?. <b>2022</b> , 118, 106782	
13	Quality of Life Outcomes of Saquinavir, Zalcitabine and Combination Saquinavir plus Zalcitabine Therapy for Adults with Advanced HIV Infection with CD4 Counts between 50 and 300 Cells/mm <sup>3</sup> . <b>1999</b> , 4, 35-44	16
12	Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial. <b>2006</b> , 11, 741-750	44
11	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. <b>2008</b> , 13, 959-967	46
10	Systemic antiviral agents. <b>2013</b> , 121-134.e2	1
9	EARLY SIGNS AND SYMPTOMS OF HIV INFECTION IN AN ALLERGY PRACTICE. <b>1997</b> , 17, 185-194	
8	TECHNIQUES USED IN ASSESSING AND MONITORING DISEASE SEVERITY AND PROGRESSION. <b>1992</b> , 12, 213-236	
7	UPDATE ON ANTIRETROVIRAL THERAPY. <b>1997</b> , 35, 995-1005	
6	STATE OF THE ART. <b>1996</b> , 31, 1-13	0
5	Medical Aspects of Care for the Person with Advanced Acquired Immunodeficiency Syndrome (AIDS): A Palliative Care Perspective. <b>1991</b> , 5, 96-111	1
4	The Pharmacologic Treatment of HIV Infection and AIDS in Adults. <b>1991</b> , 26, 315-329	0
3	ANTIRETROVIRAL THERAPY. <b>1997</b> , 24, 531-560	0
2	Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges. <b>2023</b> , 451-478	0
1	THE CLINICAL MANAGEMENT OF PATIENTS WITH HIV INFECTION AND AIDS. <b>1991</b> , 45, 202-207	0

